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Abstract: The primary motivation for this work is the manipulation of EGFR family signaling to
influence regenerative responses of mesenchymal stem cells (MSC). Underlying the potential of
regenerative medicine is the need to understand and control cell behavior. A 'cue, signal,
response' paradigm has emerged as a framework for building predictive models for manipulation
of cells to achieve desired responses. The HER receptor tyrosine kinase (RTK) family is an
attractive target for manipulation of cues and signals, as its four members - epidermal growth
factor receptor (EGFR or HERI), HER2, HER3 and HER4 - influence processes as diverse as
development, wound healing, migration, and tissue homeostasis and family members are
expressed by almost every cell type. All HER receptors require either homodimerization or
heterodimerization with other family members for activation of signaling pathways, and the
various dimer pairs are not equivalent in their ability to activate all the downstream pathways.
Hence, signaling (and phenotypic) outcomes may be dictated not only by the number (or fraction)
of each type of receptor ligated, but by the quantitative distribution of these receptors into various
possible dimer pairs. The canonical physiological ligands for the HER family receptors are
monomeric, allowing occupied receptors to freely homodimerize or heterodimerize.
The premise of this work is that engineered bivalent ligands can drive specific
dimerization events to enhance or inhibit signaling by various HER family receptors in a
quantitative fashion that might be predicted on the basis of receptor expression. This work
focuses on the design and implementation of engineered protein systems that are targeted to
control homo and heterodimerization of HERI and HER3. One broad consequence of using
homodimer ligands is to quantitatively force ligand-occupied HERI or HER3 to homodimerize
and thus inhibit heterodimerization. Homodimerization may reinforce preferred signaling
pathways (e.g, HERI-HERI vs HER1-HER2) - with implications for tissue regeneration and
inhibit undesirable pathways (e.g. HER2-HER3) - with implications in cancer. Preliminary
results suggest that whereas the monomeric HER3 ligand activates canonical signaling pathways
expected from HER3-HER2 interactions, dimeric ligands inhibit signaling, presumably by forcing
homodimerization of the kinase-inactive HER3 receptors. This thesis focuses on developing the
design principles to use bivalent ligand dimers to control signaling, experimental testing of the
hypothesis that signaling pathways can be controlled by such ligands and are quantitatively
different than those for monovalent ligands, and demonstration of how such ligands influence
proliferation of human marrow stromal cells, a cell type important for bone regeneration. In
addition, the issue of practical implementation in a tissue engineering setting is addressed by
implementing approaches to tether bivalent ligands to scaffolds in a manner that preserves
signaling function.
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1 Background and Scope
1.1 The importance of mesenchymal stem cells in tissue engineering
Mesenchymal tissues include bone, cartilage, muscle, tendon, and fat. The
differentiation of mesenchymal stem cells (MSCs) into these terminal tissue types is
governed in part by a variety of growth factors and cytokines and follows a path that is
similar to hematopoiesis in diversity and intermediate cellular states. 3 Injury and disease
in any one of the terminally differentiated mesenchymal tissues requires the recruitment
of MSCs and connective tissue progenitors (CTPs) to bring about regeneration and
wound healing. Thus the study of MSC biology figures prominently in realizing
regenerative therapies in a variety of tissues. This is of particular importance in
orthopedics which constitutes the largest clinical segment of mesenchymally-related
tissue treatments. The scarcity of MSCs currently limits the scope of what is possible. At
typical frequencies of 1 in 30,000 cells the primary engineering challenge is to overcome
a shortage of cells. Successful implementation of any tissue engineering approach
requires careful consideration of the many biological and physical parameters which
exert multifactorial effects on cells. Many of the most important questions in this field
are aimed at discovering what happens at the interfaces between cells and their
immediate environment. In the context of tissue engineering the environment typically
includes an artificial material.
1.2 Scaffold materials for MSCs tissue engineering
Exogenous materials are widely used clinically for bone regeneration. Surgical
techniques incorporating materials in mandibular bone were pioneered by Branemark in
the 1950s. Today, auto- and allo-grafts as well as synthetic P-tricalcium phosphate
(BTCP) and hydroxylapatite (HA) are common materials in bone regeneration
procedures, particularly for non-load bearing small or medium bone defects. These
approaches all rely on the recipient's own MSC population to bring about tissue
regeneration and often involve impregnation of the matrix with extracted bone marrow to
seed an appropriate number of MSCs and CTPs. In current clinical practice autologous
bone marrow aspirate containing MSCs and CTPs has been used as a source of
progenitors in both ceramic and demineralized bone grafts. Further, the success of
bone grafts in canine models of spinal fusion and segmental defect can be increased by
using methods which selectively retain MSCs , i.e., that enrich them compared non-
progenitor cells. 7-9 These methods have shown significant improvement in outcomes over
less invasive interventions, presumably due to the role of MSC delivery to the site of
injury. 10 The treatment of implants with bioactive components such as growth factors
represents a growing area of study and is likely to extend the benefits achieved thus far
with MSC enrichment.
Bone morphogenetic proteins (BMPs) and some other growth factors have gained
clinical acceptance in orthopedic medicine and are in various stages of pre-clinical
development.io, 1 BMPs, like most growth factors, are typically delivered soluble or
adsorbed to a matrix, which creates great variability in local retention and release.
Further, BMPs act on bone-forming cells to foster differentiation toward the osteogenic
phenotype, hence are arguably less effective in large defects that have a clinical
deficiency of MSCs, where driving differentiation may deplete the progenitor
compartment before it has multiplied sufficiently to fill the wound. Members of the
EGFR family act on stem cells and early progenitor cells, hence interventions targeted to
this family may increase survival and proliferation of cells at a stage that feeds into the
steps influenced by BMPs. This thesis will demonstrate precisely this effect.
1.3. Mesenchymal stromal cell biology: cues, signals, and responses in MSCs
Debate continues over how closely regeneration recapitulates development yet
analysis of developmental biology of bone and cartilage has yielded insights into factors
important in regeneration of functional bone and cartilage. In the endochondral mode of
bone formation during early stages of development bone begins to nucleate at ossification
centers within a cartilage "model". For skeletal bone the origin of these early osteogenic
cells is the embryonic mesenchyme. Ossification extends outward from primary nodes
guided by gradients in differentiation stimuli which include numerous cytokines, growth
factors, small molecules, and juxtacrine interactions. 12, 13 During early development of
cranial bones and during fracture repair later in life intramembranous ossification is the
primary mode of bone formation. This process differs from endochondral ossification in
that MSCs and CTPs play a larger role and initiate tissue formation in the absence of a
chondral supporting environment.14
Many aspects of later developmental processes leading to mature bone and
cartilage remain uncharacterized. Details such as the vacularization of trabecular bone
have yet to be elucidated.' 5 However, early bone development from cartilaginous tissue is
reasonably well characterized and can be used to inform approaches to the early
regeneration of these tissues in a wound healing context. Presentation of the correct cues
early in the wound healing process is essential for proper tissue regeneration. The cues
arising from EGFR family receptor stimulation are particularly important in this regard. 16
Epidermal growth factor (EGF)
EGF is the canonical ligand for EGFR and can bring about proliferation,1 7 -23
24-27 19migration, homeostasis, and synergistic effects leading to differentiation in concert
28-30with other ligands. - The broad effects of this ligand are due to the large number of
tissues in which EGFR is expressed and the diversity of the downstream signaling
network, thus making EGF an important stimulus in wound healing contexts.
In MSCs, EGF has been shown to affect a number of cell behaviors in a context
specific manner. EGF can promote proliferation, osteogenic differentiation,31 and
32survival. In one case EGF exerted different effects on human telomerase immortalized
MSCs (hTMSCs) and primary rat MSCs.19 In another study survival enhancement was
dependent on the surface tethering of EGF.32 In a wound healing context EGF can serve
as an important cue leading to bone development and homeostasis following surgery.33-36
EGF has also been shown to play a role as a regulator of CTP behavior 31, 37-41 and can
also give rise to expansion of MSCs without inducing differentiation.19 In addition to its
potential in wound healing applications EGF has a high degree of receptor specificity for
EGFR and thus offers an advantage in tissue engineering approaches to control EGFR
receptor dimerization, as is explained in later sections.
Neuregulin-10 (NRG1)
The effects of neuregulin1-P1 (NRG 1), the canonical ligand for HER3 and HER4,
are well characterized in neurogenesis and neurological development.- Most notably
NRG1 induces neural differentiation of rat pheochromocytoma (PC 12) cells.45 4 Its role
in neuromuscular junction (NMJ) formation is also well characterized where it serves to
stimulate acetylcholine receptor (AChR) expression at the NMJ synapse.47 NRG1 has
also been shown to enhance the ability of MSCs to repair damaged muscle tissues, thus
implicating NRG1 as a potential myogenic stimulus. 48
Recent work by Gui et al. indicates that NRG1 has a protective effect on MSCs
exposed to hypoxic or serum deprived conditions.49 Protection of MSCs in hypoxic
environments is of particular importance following surgical intervention where seeding of
MSCs into large defects will necessarily lead to hypoxic conditions in a large segment of
the wound before vascularization occurs.50 In addition to its potential as a differentiation
and hypoxia protective ligand NRG1 has a high degree of receptor specificity for HER3
and HER4 and, like EGF, is an attractive means to control dimerization of its cognate
receptors, HER3 and HER4, in a specific manner.
Integrins
Although the focus of this work is on modulating HER signaling, the cell
adhesion background impacts almost every aspect of cell behavior. The density of
integrin ligand on connective or supporting substrates provides a basis for cell adhesion
and migration which is particularly important in a wound healing context.5 ' The most
common adhesion proteins found in bone healing environments are fibronectin,
vitronectin, and collagen. In some facets of this study, the integrin ligand GRGDSP
which is present in fibronectin will be used to control the adhesion of cells to substrates
given that it has been shown to bind to both avf3 and a5pl in vitro.55 The GRGDSP
motif can be included as a fusion or bivalent partner protein with other ligands and can be
used modulate cell adhesion and migration in a systematic manner.
1.4 HER receptors and cell signaling
Since the discovery of EGF in the 1960s, the EGFR family (EGFR, HER2, HER3,
HER4) has been intensely studied and is arguably the most well-characterized peptide
growth factor signaling network.2' 19, 22, 23, 32 The HER signaling network is among the
most diverse and tightly coupled to distinct phenotypic outcomes of any network
characterized to date.1' 17, 56-61 A simplified schematic depicting the HER signaling
network is shown in figure 1.1.2 EGFR family members are receptor tyrosine kinases,
with the general structure of an extracellular ligand-binding domain, a transmembrane
domain, a cytoplasmic tyrosine kinase domain, and a cytoplasmic regulatory domain.
EGFR and HER4 possess all of these domains, while HER2 lacks a ligand-binding
domain and HER3 lacks an active tyrosine kinase.2,18,57 There are 12 known ligands that
can bind one or more of three family members (EGFR, HER3, and HER4) to give rise to
10 possible different HER homo- and hetero-dimer combinations. Ligand binding causes
conformational changes which lead to receptor dimerization and subsequent
phosphorylation of intracellular receptor tyrosines that then propagate signals into the
downstream network, which includes Erk, Akt, PI3Kand PLCy pathways.
Although many facets of ligand binding and receptor dimerization among EGFR
family members remain controversial, in part due to differences in cell types, receptor
expression levels, and experimental methods used to probe events, some generalized
features important for this thesis work can be delineated. These include:
Ligand specificity
We seek a highly selective ligand that can bind EGFR at the exclusion of other
HER receptors, thus offering control over receptor monomer binding. Likewise we seek
a ligand that can bind HER3 and HER4 selectively. Orthogonal selectivity will confer a
high level of control over receptor binding and permit construction of bivalent ligands
which can control receptor recruitment into dimer complexes. EGF has 1000X greater
....................  
affinity for EGFR than for HER3 or HER4 and is the most selective ligand for EGFR.18
Likewise NRG1-P1 (NRG1) has 5,OOOX greater affinity for HER3 and HER4 than for
EGFR.17 These two ligands will form the basis of the bivalent ligand system in this
study.
Relationship between ligand binding and receptor dimerization
Several models of HER receptor dimerization depict the dimerization event as
being induced by ligand binding; however, most of these also leave open the possibility
of HER receptors predimerizing without binding ligand. The likelihood of this event is
reduced by the conformational restrictions imposed on HER receptors in the absence of
ligand. Ligand binding stabilizes a conformational change which exposes a dimerization
loop. Dimerization in turn stabilizes the receptor dimer pair in this final conformation.
Extensive biophysical characterization of EGFR by Kuriyan and others supports this
2, 62model of HER receptor dimerization. Further evidence of this is found in the
mechanism of dimerization exhibited by HER2 which has a constitutively exposed
dimerization loop due to unique structural differences which stabilize this conformation.
Hence HER2 can dimerize with EGFR,3,4 without binding ligand.57' 63 Conversely
EGFR, HER3, & HER4 generally require at least one ligand binding event to initiate
2dimerization with another EGFR, HER3, & HER4. Thus ligand stimulation can
influence HER receptor dimerization. Some studies provide evidence that is suggestive
of pre-homodimerization of HER receptors before ligand binding. 64 However, there is
extensive evidence of heterodimerization between HER receptors, particularly with
HER2 which does not require a ligand.2, 65 Thus the question of how HER receptors
select dimer partners remains open and also suggests the possibility of influencing
receptor dimer pairings the approach described here.
Specificity of signaling pathways induced by various HER family members
High signaling diversity in the HER network is an attractive feature that can give
rise diverse phenotypic outcomes. Work by MacBeath and Jones offers a glimpse into
this complex signaling network by mapping the downstream interactome for a subset of
each HER receptor tyrosine/p-tyrosine as shown in figure 1.2.1 At first glance one can
observe well known interactions at mid nM affinities between each HER receptor and
downstream effectors. These include: EGFR(pY1172):SHC1, HER2(pY1139):GRB2, and
HER3(pY1260):Pl3K. One can generalize these findings to predict signaling network
activation and phenotypic outcomes that might result from specific receptor pairings.
This is illustrated in figures 1.1 and 3.1 which taken together capture the central premise
of this work.
The diversity and associated complexity of the HER network originate in the
receptor dimerization event. The type of ligand that initiates dimerization has some
influence on the type of receptor dimer that eventually forms and this in turn determines
the specific tyrosine residues which are phosphorylated on each receptor. In addition to
this the relative levels of each HER receptor also influences dimerization outcomes.6 3
Having a specific mechanism based on ligand specificity to control how HER receptors
dimerize might enable an additional level of control over many aspects of this signaling
network.
" SH2 domain 0 Phosphopeptide
" PTB domain 0 Non-phosphopeptide
1 iM Kjo 1.5 pM 2uM >2 pM
Figure 1.2 - The HER Y/pY interactome.1
Stimulating cells with soluble ligands from among the 12 known HER ligands
will give rise to signaling predominantly through receptors that exhibit the highest
affinities for that ligand. Dimer parings are also influenced by the relative surface
density of the various receptor types. Some ligands exhibit varying degrees of
promiscuity for several receptors. For example, betacellulin, heparin-binding EGF, and
epiregulin all can bind to EGFR and HER4 with comparable affinity.66 Other ligands
exhibit high specificity for a single receptor. EGF and NRG1$ are two such ligands and
.. .. ........ . - - - -- - MW " - - m :::: "I'll I'll .. . I'll -...... ... - ".. . ........ ......................... .
<100 nM 500 nM
each exhibits high affinity for EGFR and HER3/4, respectively. This specificity provides
a basis for controlled receptor dimerization.
1.5 Controlled HER receptor dimerization and phenotype
Seminal work by Brugge et al.67 employed genetically engineered cells to
demonstrate how cell phenotype could be driven by forcing specific homo-dimerization
and hetero-dimerization events between EGFR and HER2. This group developed a
method of controlling HER receptor dimization by engineering an intracellular fusion on
EGFR and HER2 that permits a forced homo- or heterodimerization by way of a bridging
small molecule, either rapamycin or AP1510. This study identified a number of
differences in both signaling and phenotype resulting from forced homo- and
heterodimerization between EGFR and HER2 in fibroblasts. The first important finding
was that activation of HER homodimers results in induction of cell cycle progression,
receptor tyrosine phosphorylation, and recruitment of Src homology 2 domain-containing
proteins (Shc and Grb2) which lead to pErk2 and pAkt signaling. Interestingly they
confirmed that only EGFR homodimers were internalized and only EGFR homodimers
were able to associate with and induce phosphorylation of c-Cbl. Cells with forced
EGFR homodimers were able to form foci; however, cells with forced HER2
homodimers displayed a five- to sevenfold higher focus-forming ability. Lastly they
found that EGFR and HER2 homodimers differ in their abilities to transform fibroblasts.
The results of this study demonstrate the utility of forced HER receptor
dimerization to control phenotypic outcomes. This approach however is not amenable to
exogenous control as it requires expression of chimeric variants of the HER receptors.
Any clinically useful strategies in this area will require completely exogenous control
over HER receptor dimerization as genetic intervention is not feasible or approved.
1.6 Biomaterials and Scaffolds
The clinical utility of any results from HER ligand engineering would be
enhanced if those results could be replicated on biomaterials and scaffolds that are
currently used in surgical procedures. One such substrate is P-tricalcium phosphate
(BTCP) which is used in orthopedic procedures as bone void filler.68 Often this material
is flushed with bone marrow aspirate to seed MSCs and promote bone formation.69
BTCP is an osteoconductive material that supports bone mineralization by easily
dissolving at low pH and serves as a rigid substrate for cell attachment.21' 69
One drawback of BTCP is the lack of available surface treatments to functionalize
this material. No reliable methods to treat the surface of BTCP with proteins or similar
coatings are described in the literature or in clinical case studies. Flushing BTCP with
bone marrow aspirate is the current state of the art in BTCP surface treatment; however,
this produces a highly heterogeneous distribution and uncontrolled adhesion of serum
proteins. Attempts to make polymer composites with BTCP have shown some promise
but these new materials require extensive characterization and regulatory approvals. The
utility of BTCP as a substrate for orthopedic procedures would be enhanced if surface
treatments were available to permit direct attachment of bioactive components. The
ability to tether ligands and other bioactive components to the surface of BTCP implants
would bring improvements in patient outcomes and would open the field to spatially
guided tissue regeneration. This is of particular importance in the vascularization of
regenerated bone tissue.
One approach to this problem is to attempt discovery of peptide sequences that
exhibit tight binding to BTCP by using phage display. Preliminary results from a 12-mer
unconstrained phage panning experiment on BTCP have produced promising results.
The details of this work are given in Chapter 4. One objective is to discover optimized
configurations of multiple n-mer binding peptides that can be used as fusion partners to
confer tight binding of ligands to BTCP substrates. The engineered proteins described in
this study incorporate features which permit fusion to optimized BTCP binding peptides.
1.7 Outline of Thesis
The overall objective of this work is to develop new molecular approaches to
control cellular outcomes that will have clinical significance in regenerative medical
applications, and is addressed in three major aims. The first focuses on the design and
biochemical characterization of ligands to control HER receptor dimerization; covered in
chapter 2. The second aim consists of detailed characterization of the bivalent ligands to
determine impact on HER dimerization in both model cells lines (ie., lines with defined
HER expression profiles) and in the practical target cell of of application, MSCs; covered
in chapter 3. The last aim focuses on the characterization of engineered HER ligands in
tethered form and will explore the effect on MSCs of tethered ligand presentation on
clinically important materials; covered in chapter 4. The last chapter will summarize the
conclusions of this work. Various appendices include detailed protocols, information on
protein expression constructs, and discussion of future directions.
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2 Design and Synthesis of Bivalent Ligands
2.1 Introduction
The approach taken in this work to exert control over HER receptor dimerization is to
design a panel of ligands that can recruit specific receptors into dimer complexes based
on the affinity and specificity of natural ligand-receptor interactions within the HER
receptor family. Such bivalent dimer ligands should bias dimerization. This chapter
addresses the design and synthesis of this panel of ligands and details the protein-based
characterizations required to validate the design features of the final products.
2.2 Protein design and characterization
The design of ligands is first guided by the dimerization geometry of HER
receptors when bound to ligand. This geometry is most precisely described by the 2 A
crystal structure of the EGF-bound homodimerized extracellular domain of EGFR (figure
2.1).' This figure shows that wild-type ligands assume an anti-parallel orientation with
respect to their termini when bound to dimerized receptor and that the distance between
ligands is approximately 10 nm.
EGF N-terminus-Tp
EGF C-tenninus
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l~98 A
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Figure 2.1 - Crystal structure of EGFR extracellular domain liganded with two
EGFs
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These features inform the initial design of the bivalent ligand system by imposing
constraints on the minimum length between ligand domains and on the relative
orientation of ligands once bound to dimerized receptor. Further, the five terminal amino
acid residues on both termini of EGF are not captured in the crystal structure, indicating
that these residues are unstructured and do not participate in receptor binding. Taken
together these features describe the geometric parameters required for bivalent ligand
binding. The overall design must accommodate these features if it is to achieve its stated
purpose.
2.2.1 Modular Bivalent Ligand Design
A modular protein design can facilitate the investigation of homo- as well as
heterodimers in both EGFR and HER3 without requiring repetitive cloning, expression,
and purification. The bivalent design with modularity can be realized by using a tight
binding region that brings ligands together with the correct orientation and spacing to
permit simultaneous receptor dimer binding. One implementation of this design is shown
in figure 2.2. As illustrated a coiled-coil domain allows for cognate coil containing
ligands to form a bivalent structure. The coil sequences were selected from previously
published work and have been reported by several investigators to exhibit a Kd as low as
101 M.2-4
The coils are separated from the ligand by a protease resistant spacer designed by
Sauer et al. that confers flexibility, solubility, and together with the coils a sufficient
extension to bridge a gap 20 nm long.: This is twice the distance between the most
extreme termini in EGFs bound to dimeric EGFR. A schematic of the bivalent ligand is
shown in figure 2.2, which also depicts additional functional moieties, including antibody
detection epitopes, and a biotin acceptor peptide (BAP) sequence to permit biotinylation
and subsequent immobilization on neutravidin coated matrices.
EGF 4H2 NRGP-1
-110-200 A '
NRG-2
NRG-3
Epiregulin
4WWWWWWI-TGF-a20 AA Peptide
Linker
Heterospecific Coiled Coil Linker
-2 pM Binding Affinity Biotin Acceptor Peptide
Scaffold
Figure 2.2 - Bivalent ligand design
The formation of a bivalent structure is mediated by a tight binding coiled coil
interaction. This permits the formation of various bivalent ligand compositions.
The components of this system are shown in table 2.1. A modular design allows
the formation of bivalent EGF "EE", bivalent EGF-NRG "EN" (a mixed ligand), or
bivalent NRG "NN". The monomeric ligands that serve as the components of this system
are denoted Cl and C2 (the EGF containing ligands), and C3 and C4 (the NRG
containing ligands). Based on the coiled heterospecificities the following bivalent
ligands can be formed: C12 ("EE"), C13 ("EN), C24 ("EN"), C34 ("NN"). The panel
exhibits a degeneracy of one in the mixed ligand combination "EN". The C13
combination was used for all studies of the EN bivalent ligand, unless otherwise noted.
.................................................................   ........ :::::::-    ........ ..................... 
Name Ligand Type Can Pair Biotin Acceptor
C1 EGF C2 or C3 Yes
C2 EGF C1 orC4 No
C3 NRG C1orC4 No
C4 NRG C3orC2 Yes
Table 2.1 - List of ligand components by type, bivalent binding partner, and
presence of a biotin acceptor peptide sequence
2.2.2 Cloning and Protein Expression
Coding DNA for fusion proteins consisting of the human sequences of EGF or
NRG-lb domains fused to protease resistant hydrophilic spacer arms fused to coiled coil
domains followed by biotinylation sequences and epitopte tags (as per Table 2.1) were
designed in silico (using VectorNTI) then ordered as a whole gene product with an E.coli
codon bias from GeneArt (Regensburg, Germany). Coding sequences were amplified by
PCR mutagensis with flanking restriction sites to permit cloning into expression vectors.
Intially two T7 promoter based expression systems were used to produce the
ligand components: a pET28(a) His-tagged system (Novagen) for C1 and C4; and a
maltose binding protein (MBP) tagged system: pMAL-c2X (New England Biolabs) for
C2 and C3. The pET28a vector tended to produce inclusion bodies which require
solubilitzation in 6 M urea + 100 mM dithiothretol followed by dialysis against a
refolding buffer of reduced and oxidized glutathione.
Evaluation of both expression systems revealed that the pMAL system was far
superior in that it could produce large quantities of properly folded soluble protein and
did not require the difficult isolation of inclusion bodies, denaturnation, extensive
refolding, and subsequent separation of mis-folded isomers by reverse phase
chromatography. This advantage represented a ten fold improvement in performance
over the pET expression system in terms of time and materials required. As a result, C1
and C4 were removed from the pET backbone and cloned into pMALc2x expression
vectors (NEB) and used as such for all experiments.
All expression constructs were sequenced prior to transformation into the
expression strain BL21(DE3)pLysS (Stratagene). Transformed strains were grown to
OD-0.6 with agitation at 37'C. Cultures were then brought to 250C and protein
expression was induced with a single pulse of 100 nM IPTG for 4 hours. Protein was
harvested following cell lysis with Bug Buster Master Mix reagent (Novagen)
supplemented with PMSF and protease inhibitor cocktail (Sigma).
Lysates were clarified by centrifugation at 3500g for 1 hour at 40C. Clear lysate
was subjected to purification on amylose resin in accordance with the pMAL System
protocol (New England Biolabs). Eluted protein was concentrated using an
ultracentrifugation cassette (10 kDa MWCO, Pierce). Purification tags were cleaved by
factor Xa digestion overnight at 300C in 20 mM tris, pH 7.4.
2.3 Validating Protein Identity
Purified proteins were analyzed by coomassie staining of sodiumdodecylsulphate
polyacrylamide gels (SDS-PAGE), immunoblot, mass spectrometry, absorbance at 280
nm (A280), and in vitro cell response vs wild type ligands EGF and NRG-1@P (Peprotech).
A representative set of Coomassie and immunoblot analyses is shown in figure 2.3.
Coomassie staining gives estimated molecular weight and relative purity. Typical
purities ranged from 80-95%. Immunoblots confirm the presence of full length protein
when probed for terminal epitopes as shown in figure 2.X.
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Figure 2.3 - Characterization of expressed proteins
(Top) Coomassie stained SDS-PAGE gel of purified C2 and C3. The purity and
estimated molecular weights of the purified proteins are evident from the rightmost two
lanes. (Bottom) Immunoblots of ligands (cut indicates cleaved with factor Xa); spot blots
confirm absence of EGF from NRG containing C3 and C4. Probing blots with
streptavidin-800IRDye confirms the presence of biotin on C1 and C4 (the BAP is a C-
terminal sequence on each protein).
2.3.1 Confirming ligand bioactivity
Bioactivity of purified fractions was confirmed by in vitro cell response vs wild
type ligands EGF and NRG-1 (Peprotech). Specificity for HER receptor activation was
further assessed by including inhibitor controls using the pan-Her kinase inhibitor N-(4-
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((3 -Chloro-4-fluorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)2-butynamide
(Calbiochem #324840). Bioactivity and HER specificity were validated in HeLa and
MCF-7 cells (for EGF and NRG containing ligands, respectively). HeLa cells express
EGFR and HER2 and are responsive to EGF while MCF-7 cells express HER3 and
HER4 and are responsive to NRG. Figure 2.4 is an immunoblot of pERK(1/2)
stimulation following ligand dosing.
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Figure 2.4 -Ligand bioactivity assay
EGF containing ligands (Cl and C2) were used to stimulate HeLa cells and
compared with wt EGF stimulation. NRG containing ligands were likewise
evalutated in MCF-7 cells.
The singly-dosed ligands produce pERK activation which is indistinguishable
from their native analogues, and which is capable of being specifically inhibited by a
pan-HER kinase inhibitor. This assay illustrates the effectiveness of the purification
methods and validates the use of these ligands for use in bivalent experiments.
2.3.2 Biotinylation of Ligands
Incorporation of a tethering motif into the ligand design allows for greater
flexibility in surface immobilization on tissue engineering scaffolds and for purposes of
. ................................ ....  
detection. The biotin-streptavidin interaction is one of the tightest non-covalent
interactions known (kD-10' 5 M) and is essentially irreversible over a broad range of
conditions. The incorporation of a biotin acceptor peptide (BAP) sequence as a terminal
fusion to C1 and C4 permits the biotinylation of these ligands and subsequent
immobilization via interaction with immobilized streptavidin. The BAP is a 15 amino
acid sequence that acts as a substrate for biotin ligase (BirA).
During expression in E. coli some fraction of the ligand is biotinylated by
endogenous BirA. To achieve a higher level of biotinylation (>80%) exogenous BirA
can be used following ligand purification. The degree of biotinylation can be measured
by the degree of change in absorbance of 4'-hydroxyazobenzene-2-carboxylic acid
(HABA) at 500 nm. Assays based on this sensor report the percentage of ligand that is
biotinylated. In addition to quantitative assays the biotinylation of ligand can be detected
by spotting on a nitrocellulose membrane and probing with IR-fluorescently labeled
streptavidin and by SPR analysis with a streptavidin coated gold chip. Biotinylated
ligands can be used in a variety of experimental schemes which incorporate a streptavidin
(neutravidin or captavidin) tethering surface. Details to accomplish this are described in
later sections.
2.4 Characterizing the Coiled Coil Interaction
The first generation of coils selected was from work published by Arndt and
produced an interaction which exhibited mico-molar affinity as shown in figure 2.5. 6, 7
This set of coils was replaced with a modified set of coils by site directed mutagenesis of
the original construct. When assayed by an enhanced immuno-fluorescence binding
method the new coils yielded a Kd of - 30 pM. This figure is approximately two orders
of magnitude below the lowest relevant dose of EGF or NRG used in vitro and would
ensure complete binding of the bivalent components.
2.4.1 Immunofluorescent Binding Assay
Characterization of the coiled coil interaction shown in figure 2.2 was performed
by an immuno-fluorescent binding assay on streptavidin coated wells. Biotinylated C1
was incubated on the well surface and a titration of cognate coil concentrations was used
to generate a binding curve. Controls include non-biotinylated ligand to measure non-
specific adsorption and staining of biotinylated ligand with 20 antibody to control for
variations in bound ligand. Fitting these data to a one-parameter binding isotherm gives a
Kd of 30 pM.
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Figure 2.5 - Immunofluorescent binding assay
An ELISA based method using streptavidin coated EIA plates as used to
achieve very sensitive detection of bound ligand. n=3, +/- s.d.
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2.4.2 Far Western Blotting
Coiled coil binding was also investigated using far-western blotting. This was
carried out by spotting 0.5 ul of sample ligand binding partner and controls in duplicate at
1 jiM concentration onto a nitrocellulose membrane that was pre-wetted with 1 X transfer
10 probe (Cl-biotin) 20 Probe (S-800)
Only cognate
Spot Membrane coils 
bind
sample (-) (+)
Figure 2.6 - Far western analysis of coiled coil interaction
C2, C4 and Cl(control) protein are spotted in duplicate onto a nitrocellulose membrane
(labeled C2, C4, and Cl in red, bottom). The membrane is then probed with soluble C1 to
allow binding between Cl and C2. Evidence of binding is seen in the positive signal seen
over the two C2 spots. The negative control C4 should not bind Cl and is shown to
produce only background signal. Cl is spotted directly (positive control, rightmost spots).
Membrane was probed with streptavidin-800 IR dye to detect biotinylated Cl.
buffer (4:1 MQ water:methanol and MES buffer). Membranes were washed three times
with 20 mM tris-buffered saline + tween-20 (TBST), pH 7.4 (TBST) then blocked for 1
hour with Licor Odyssey blocking buffer (OBB) then biotinylated cognate binding
proteins were added to the blocking buffer at 100 nM and incubated overnight at 4"C.
The membranes were then washed three times with TBST and probed for 1 hour with IR
dye conjugated streptavidin (Rockland #) diluted 1:10,000 in OBB. The membranes
were then washed three times in TBST and scanned on a Licor Odyssey IR scanner.
Figure 2.6 illustrates the experimental concept and the resulting data. Binding due to the
coiled coil interaction is evident from the significant signal in the cognate binding pair
C1+C2.
2.4.3 Surface Plasmon Resonance
Surface plasmon resonance was performed on a Biacor2000 instrument using a
streptavidin coated gold analysis chip. Biotinylated Cl was immobilized on the chip
surface and brought to equilibrium with running buffer. The conjugation of C1 to the
chip surface exhibited a stable baseline within a 90 seconds of flowing Cl and remained
stable over long buffer wash times, indicating a stable surface binding of Cl. Attempts to
conjugate additional C1 showed no change in the based line, indicating saturation of the
chip surface.
Cognate binding partner C2 was then flowed over the surface and binding signal
collected. Figure 2.7 shows data from the biotin - streptavidin chip conjugation and the
C2 binding analysis. Data analysis is performed on the separate binding and unbinding
portions of the response curve. During binding the partner in the mobile phase (C2)
undergoes both binding an unbinding and so the data produced contain a combination of
both effects. This is captured in the lumped variable called kobs as shown in equation 2.1.
The unbinding portion of the data reflects purely unbinding since the mobile phase does
not contain appreciable amounts of C2 during this step. The pure unbinding is captured
by kort as shown in equation 2.2. In order to obtain the on rate during the binding step the
kobs is transformed by subtracting koff and normalizing by the ligand concentration in the
mobile phase during the binding step. In this way both koff and kon are obtained, allowing
the dissociation constant to be calculated as shown in equation 2.4.
S(t) = S +S (1-- ekbs t ) (2.1)
S(t) = S + S,e "'' ' (2.2)
kog - k
ko,, - Cbs off (2.3)[C2]
k
K= off (2.4)
kon
The data produced by SPR are generally acceptable for binding affinities weaker than
low nanomolar. Very tight binding interactions that are high picomolar and below
generally produce data which cannot be fit reliably with the approach outlined above.
This happens to be the case for the binding interaction between C1 and C2. As seen in
figure 2.7 the kon fitting gives a non-physical value. This can be interpreted as an effect
of the extremely tight binding of this coil pair. The binding affinity obtained from the
immunofluorescent binding assay (30 pM) confirms this effect.
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Figure 2.7 - Surface plasmon resonance analysis of coiled coil interaction
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2.4.4 Isothermal titration calorimetry
Isothermal titration calorimetry can be used to study interactions between proteins
with dissociation constants that are between 100 nM - 100 uM. The ability of this
method to detect very tight interactions is limited by the ability to track changes in
differential heat transfer that occur over a small range of titration volumes. This effect is
illustrated in figure 2.8 by the sharp transition observed at 90 minutes. Although these
data cannot be fit to obtain a binding constant they are suggestive of previous results of
an extremely tight binding interaction. (additional analysis of binding will be included in
the manuscript and will include analytical ultracentrifugation data.)
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Figure 2.8 - Isothermal titration calorimetry of C1 and C2
The tight binding interaction between the cognate coils produces a very sharp
transition consistent with very tight binding.
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2.5 Conclusions
This chapter has outlined the methods used to design and characterize a panel of
genetically encoded ligands with motifs to permit biotinylation, dimerization, and
specific biological activity. The design was successfully implemented and the panel of
ligands was shown to exhibit the expected binding characteristics and bioactivity
necessary for subsequent experiments. The groundwork laid here is a necessary
prerequisite for biological studies using this panel of ligands. Subsequent chapters will
investigate the effects of bivalent ligands on various cell types.
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3 Influence of Soluble Bivalent Ligands on Cell Signaling & Phenotype
3.1 Introduction
Overwhelming evidence supports the concept that EGFR family members must
homo- or hetero-dimerize in order to initiate intracellular signaling events, and that ligand
binding to at least one dimer member is required under most normal physiological
circumstances.1, 2 However, the sequence of events leading to an active ligand-occupied
receptor dimer pair is still debated and may ultimately depend on the cellular context. In
the canonical model, applicable to the ligand-binding receptors EGFR, HER3 and HER4,
receptors exist on the surface in a closed configuration stabilized by interactions between
extracellular subdomains II and IV.3 When ligand binds, the receptor opens and adopts a
new stable configuration, exposing a "dimerization arm" on the extracellular domain,
leading to creation of dimers stabilized by both extracellular and intracellular domains of
the receptor. 3-6 An alternate model, supported by experimental data from several labs,
holds that receptors exist in pre-formed dimers or higher-level aggregates, 7- but that
activation requires conformational changes induced by ligand binding. 4' " HER2 does
not precisely fit either model, as it has no known ligands and is constitutively present in a
conformation with the dimerization loop exposed to allow heterodimerization with
EGFR, HER3, and HER4, even in the absence of ligand.1, 2, 12 Notably, cells that
overexpress HER2 - i.e., that express HER2 at levels associated with some pathology -
have constitutively active HER2 due to homodimerization.13 Thus, bivalent ligands may
serve to drive particular dimerization events between lone receptors; to stabilize pre-
existing dimers; or to disrupt pre-existing unoccupied receptor interactions (such as
HER3 clusters) and drive new ones. Although certain outcomes might be predicted from
consideration of "equilibrium binding" at the cell surface, the observed outcomes will
result from the integrated kinetics of ligand binding, receptor diffusion in the membrane,
and receptor internalization and are thus not intuitive to predict.
For all members of the EGFR family, signal attenuation is achieved by at least
two known mechanisms: tyrosine phosphatase deactivation; and receptor internalization
and intracellular trafficking to lysomal degradation.14' 15 Upon ligand binding, EGFR is
internalized within minutes and later degraded in lyzosomes. 16 The internalization
depends on the dimerization status, as HER2 heterodimerization with EGFR decreases
the internalization rate constant for EGFR and increases the fraction of EGFR recycled to
the cell surface following internalization. 17 Dimer composition can also affect the
relative rate of dephosphorylation by altering the trafficking and localization of a
liganded receptor dimer as well as by differentially recruiting phosphatases to adaptor
sites.
Much of our understanding of the HER receptor signaling pathway comes from
studies with either natural or deliberate genetic mutations of ligands and receptors in cell
lines, and use of inibitors of binding and signaling. The development of the bivalent
ligand system described in Chapter 2 allows a new approach to manipulating the HER
system by using a purely exogeous method, in the form of bivalent ligands, to form
selective HER dimers as shown in figure 3.1. The central hypothesis of this work is that
stimulation with bivalent ligands can bias receptor dimerization outcomes in a predictable
way.
3.1.1 Biasing EGFR Family Receptor Dimerization
Figure 3.1 depicts possible outcomes of HER receptor dimerization when a cell
expressing all four types of HER receptors is stimulated with either wild type
(monovalent) ligands (EGF or NRG) or with dimer ligands (EE, EN, or NN). Although
few cells express appreciable amounts of all four receptors, the figure illustrates the key
conceptual innovation in this work: stimulation with dimer ligands can potentially bias
the degree of homo- or hetero-dimerization, with the practical outcome of either fostering
formation of desirable dimerizations, or excluding potentially deleterious dimerizations
(e.g., sequestering HER3 in inactive pairs; preventing EGFR-HER2 dimers). In addition
to the dimeric outcomes illustrated in Fig 3.1, it is also conceivable that a bivalent ligand
could lead to formation of oligomers, by serving as a bridge between two different
adjacent receptor dimers.
The quantitative outcome of stimulation by either monovalent or bivalent ligand
is expected to depend on both the absolute number of reach EGFR family member
expressed as well as the relative numbers. For example, in cells that express high levels
of any single receptor (>200,000 per cell), pre-formed receptor dimers may dominate
effects of ligand dimers. Although in theory, the EGF-EGF ligand dimer should drive
EGFR homodimerization and thereby inhibit EGFR-HER2 heterodimerization, it may be
difficult to prevent EGFR-HER2 dimers from forming when stimulating tumor cells that
overexpress one or both receptors. Thus, a particular dimer ligand may exert very
different phenotypic and signaling responses in epithelial cells expressing high levels of
multiple EGFR receptor family members compared to mesenchymal stem cells, which
express EGFR, HER2 and HER3 at levels below 10,000 receptors/cell, and do not
express HER4.
Despite the complexity of how the context of an individual cell may influence
outcomes, it is possible to make some general predictions about how particular types of
receptor biasing might influence downstream signaling based on what is known about the
signaling pathways initiated by each HER receptor dimer. For example, activation of the
HERI homodimer could be expected to produce increases in pERK leading to
proliferative signaling that are weaker than those produced by HER1-HER2
heterodimers.' 8 EGFR homodimers are trafficked via endocytosis at a higher rate than its
heterodimers and so preferential recruitment of EGFR homodimers might result in
increased receptor internalization and degradation.1 8
Bivalent dimers of EGF-NRG would bring together HER1-HER3 or HER1-HER4
heterodimers and would likely give rise to canonical HER1 signaling through STAT3 as
well as HER3 mediated P13K signaling.19 The phenotypic outcomes resulting from this
type of stimulation will likely depend on the relative expression levels of the various
HER receptors with respect to each other.
The EGF-NRG bivalent ligand may reduce the mitogenic signaling that arises
from the free association between HER2 and HER3 that normally occurs in cells
expressing high amounts of these receptors.2 The HER2-3 heterodimer is the most
potent mitogenic pair in certain tumor cell types, hence inhibiting heterodimerization
with N-N bivalent ligands may have therapeutic potential.
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Figure 3.1 - HER receptor dimerization outcomes
Stimulation of cells expressing different HER receptors with wild type
monovalent ligands gives rise to heterogeneous distributions of HER dimers
(dotted box). Bivalent ligand stimulation is predicted to bias receptor
dimerization as shown in the lower panel. (Figure adapted from S. de Picciotto).
Stimulation of cells expressing HER3 along with EGFR or HER2 and lacking HER4
using the N-N homodimer is expected to silence HER3-mediated signaling because
HER3 receptors are kinase deficient and must heterodimerize to signal. As NRG also
binds with high affinity to HER4, stimulation of cells expressing both HER3 and HER4
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(a relatively uncommon situation) will have a complex response that might be parsed
using inhibitors that block binding to HER4.
Finally, the effects of dimer ligands are likely to depend on dose in a complex
manner. Although we expect the ligands to bind in bivalent fashion at low ligand
concentrations, at concentrations an order or magnitude or more above KD and where
ligand is in great excess over receptor they may bind in monovalent fashion. Under such
circumstances, the ultimate cell response may still be different than that observed for
binding of true monovalent ligand, as the bivalent ligands may influence interactions with
other receptors, internalization, or other events.
3.1.2 Rationale for Choice of Cell Lines used in Signaling and Phenotypic Studies
The primary motivation for work conducted in this thesis is manipulation of
EGFR family signaling to influence regenerative responses of mesenchymal stem cells
(MSC). Signaling by members of the EGFR family has been implicated in numerous
facets of bone development, homeostasis, and regeneration.2 2 Human MSC, even very
early after isolation from marrow, express EGFR, HER2, and HER3 but no detectable
levels of HER4.23 The expression levels of EGFR family members in both an hTERT-
immortalized human MSC line and in primary bone marrow-derived MSC are relatively
low and regulated by culture conditions: EGFR is expressed at 5,000- 10,000 copies per
cell, HER2 at about half the level of EGFR, and HER3 at low but detectable levels. 19' 23
It is expected that all monovalent and bivalent NRG stimulation acts through HER3, as
MSC do not express detectable levels of HER4. Hence, in MSC, we expect that all three
bivalent ligands - EE, EN, and NN - will exert different effects than their monovalent
counterparts through biasing EGFR homodimers at the expense of EGFR-HER2
heterodimers (EE), inhibiting HER3 signaling by preventing heterodimerization with
HER2 or EGFR (NN), and driving EGFR-HER3 heterodimers at the expense of the more
highly favored HER3-HER2 heterodimers (EN). Phenotypic responses of MSC to EGFR
family ligands include colony formation, survival, growth, migration and differentiation.
Although the MSC system is attractive for regeneration medicine, it has limitations for
exploring the effects of bivalent EGFR family ligands on cell signaling and phenotypic
responses. Many phenotypic responses have been studied; however, relatively few
investigations have focused on EGFR family-mediated signaling in MSCs. Because
these cells have relatively few receptors, some signaling responses may be at the limit of
detection with available reagents, even though phenotypic responses are robust. The
relative paucity of receptors is also representative of only one end of the spectrum of
parameter space of interest - cells with one or more EGFR family members highly
expressed may represent a different regime of balance between binding and signaling
phenomena by virtue of having a different dynamic equilibrium among dimer states.
Therefore, in addition to analyzing responses in human MSC, we investigated
responses in two epithelial tumor lines that express select EGFR family members at
relatively high levels and have well-characterized EGFR family-mediated behaviors.
HeLa cells, a cervical cancer-derived line that is often used as a model of EGFR-
mediated signaling, have relatively high EGFR and HER2 expression (-50,000 surface
receptors for both EGFR and HER2) with robust response to EGF treatment and low
HER3 and HER4 expression with weak response to NRG treatment.2 Because HeLa
cells express roughly comparable levels of EGFR and HER2, and EGFR-HER2
heterodimers signal more robustly for growth than do EGFR-EGFR homodimers, HeLa
cells would likely respond to EE ligand dimers by exhibiting both a HER2
phosphorylation level and a level of proliferation that is between monomeric EGF-
stimulated and completely unstimulated HeLa cells. Thus HeLa cells are well suited to
characterize bivalent ligands which contain EGF.
As a model cell system for analyzing cell responses to bivalent ligands containing
NRG, without confounding effects of high EGFR expression, we use the mammary tumor
line MCF-7, which express HER3 at relatively high levels, and EGFR at relatively low
levels (<5000 EGFR/cell). MCF7 cells also express low levels of HER2 and HER4,
exhibit a robust response to NRG stimulation, and have well characterized HER3
signaling pathways. Because MCF7 express HER4, and antibodies that block NRG
binding to HER4 are available, these cells represent an especially useful model to screen
primary phenomena occurring during stimulation with NRG-containing bivalent ligands.
It is expected that MCF-7 and other HER3-dependent cancer cell lines may respond to N-
N ligand dimers by forming HER3 homodimers thus becoming quiescent or apoptotic
due to the kinase deficiency of HER3 and sequestration of HER3 receptors into silent
complexes; this effect would likely be mitigated in cells (such as MCF7) that also express
HER4.
3.2 Materials and Methods
3.2.1 Cell Culture
Human telomerase reverse transcriptase (hTERT)-immortalized human
Mesenchymal Stem Cells (hTMSC) were a gift from Dr. Junya Toguchida (Kyoto
University, Kyoto, Japan). HeLa cells were obtained from (ATCC). HeLa and htMSCs
were maintained in Dulbecco's modified Eagle's medium (DMEM) containing: 10% fetal
bovine serum (FBS), 1% L-glutamine, and 1% penicillin/streptomycin at 37'C, 95%
humidity, and 5% C02. MCF7 cells were maintained in phenol red free medium of the
same composition and under the same incubation conditions. For single-cell migration
studies, hTMSCs were maintained in a DMEM medium containing: 0.5% dialyzed fetal
bovine serum (FBS), 1% L-glutamine, and 1% penicillin/streptomycin at 37'C, 95%
humidity, and 5% C02.
Cells were washed with PBS at 37'C and trypsinized. Once the cells had
detached, trypsin action was blocked by adding growth medium. Cell solution was then
centrifuged for 3 minutes at 500rpm at 4'C. The solution was then aspirated and the
pellet was resuspended in quiescent medium - Dulbecco's modified Eagle's medium
(DMEM), 0.5% dialyzed FBS (dFBS), 1mM pyruvate, 1mM L-glutamine, 1 1tM
nonessential amino acids, and 100 units/ml penicillin-streptomycin (Invitrogen) - to
obtain a concentration of 300'000 cells per ml. In a twelve-well plate, 1 ml of cell
solution was added per well (area is 3.8 cm2). After 16-20 hours, medium was aspirated
and replaced with stimulation medium (quiescent medium containing ligand at known
concentration). The ligand solutions were prepared just before stimulation and
maintained at 37'C. After stimulation the lysates were collected according to
phophoprotein assay protocols (described in the next section).
3.2.2 Phosphoprotein Assays
Cell signaling data of common nodes (pERKI/2, pEGFR, pHER3, pHER3,
pHER4, etc.) were collected using standard immunobloting, in-cell western, or Luminex
assay (Biorad). Immunoblotting was performed by normalizing cell lysates to total
protein content as determined by BCA assay (Pierce) and running on SDS-PAGE 4-12%
tris-acetate gels (Invitrogen). These were transferred to nitrocellulose then probed with
corresponding primary antibodies (9106 pERK, 2236 pEGFR, 4791 pHER3, 4757
pHER4, Cell Signaling) and secondary IR-Dye conjugate antibodies (IR-Dye700/800,
Rockland). Membranes were scanned using a Licor Odyssey IR scanner (Licor Systems,
Inc.). In cell western analyses were similarly performed in black-walled 96 well plates
and using correspondingly higher dilutions of antibodies.
Novagen bead kits were used for phosphorylated HER2 (pTyr) and total EGFR
and HER2 determination (EMD Sciences), and Bioplex bead kits were used for
phosphorylated ERK/2 (Thr 202/Tyr 2O4, Thri 5 /fyri8 7). Phosphorylated EGFR (pTyr)
determination was performed with Bioplex bead kits for dose responses and with
Novagen bead kits for time courses. The fluorescent beads are coated with antibodies that
bind target proteins in cells lysates and the assays are designed to work with a Bioplex
200 System (BioRad, Luminex technology). Linearity of the pTyrEGFR and pERK
Bio-Rad assays was checked using varying ratios of stimulated lysates from hTMSC and
results were used to determine the optimal loading per well. For phosphoprotein detection
10 Rg of protein lysates and 5 [tg for total protein detection from each sample were
incubated overnight in filter plates (Millipore) with the appropriate antibody-bead
conjugates. Unbound proteins were washed away by vacuum filtration of the plate,
trapping the beads in the well. Beads were rinsed with vendor-supplied buffers and
incubated with a biotinylated antibody specific for a second epitope on the target. Beads
were rinsed again and incubated with streptavidin phycoerythin (Strep-PE), fluorescently
tagging the antibody bound to the second epitope. The beads are intrinsically fluorescent
at a wavelength matched to the target protein in the Bioplex software, hence, intensity of
PE fluorescence relative to the fiduciary fluorescence of the bead allows quantification of
the target protein. Total EGFR and HER2 fluorescence was normalized to a standard
curve generated with increasing concentrations of the extracellular domain of EGFR
provided by the manufacturer (Novagen). Phosphorylated protein signals were
normalized to the signal of an unstimulated lysate for the time course experiments.
3.2.3 In vitro inhibition experiments.
Low passage MCF7 cells (ATCC) were plated into 12 well plates at 250,000 cells
per well in serum containing medium and incubated for 48 hours. Cells were then serum
starved for 5 hours prior to ligand treatment. Inhibition experiments which blocked
HER4 with anti-HER4 antibody clone H4.72.8 (Millipore # 05-478) were pretreated with
10 uM antibody 30 minutes prior to subsequent treatments. IC50 measurements were
made by dosing cells with concentrations of bivalent NRG ligand (C34) in the range of 1
uM to 1 fM for 10 minutes followed by a pulse of 3 nM NRG for an additional 10
minutes (this dose of NRG and endpoint time were validated by generating a NRG dose
response curve for MCF-7s in the concentration range 1 uM to 1 fM for 20 minutes. 3nM
NRG was the lowest dose that produced near maximal pERK signal at 20 minutes, data
not shown). Following all stimulation experiments cells were placed on ice, medium
aspirated, washed with ice cold PBS, and lysed with lysis buffer Calbiochem #
FNNOOl1; 10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF,
20 mM Na4P207, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5%
deoxycholate, 1 mM PMSF, protease inhibitor cocktail (Sigma Cat. # P-2714) and two
phosphatase inhibitor cocktails (Sigma Cat. #P28504 and P5726).
3.2.3 Cell Survival and Apoptosis Assays
MCF7 cells were treated as described above an evaluated for viability at various
timepoints post treatment. Cells were subjected to either a flow cytometric assay to
measure the PI positive population or terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) staining. PI staining was performed by diluting PI in growth
medium following resuspension of trypsinized cells from each condition. Cells were then
directly read on an Acuri Flow cytometer. Unstained MCF7 cells were used as a negative
control to set the analysis gate and calculate percent PI positive. TUNEL staining was
performed on cells according to the manufacturer's instructions (Trevingen).
3.2.4 Migration Assays
Transwell Assays
HTS Fluoroblock transwell well chambers (Beckton Dickinson) for a 24 well
plate format were seeded with hTMSCs in expansion medium supplemented with
mitomycin-c. After seeding and attachment for 2 hours the chambers were transferred to
their respective conditions and cells were allowed to migrate for 12 hours. At the end of
the experiment the upper chambers were transferred to 4% formaldehyde, washed twice
in PBS then incubated in Sytox-16 nuclear stain (Invitrogen) for 15 minutes. These were
again washed with PBS then placed in a clean 24 well plate and read using a SpectraMax
M2e multi-well fluorescent plate reader (Molecular Devices Corp.CA, USA). A standard
curve correlating fluorescence with cell number was obtained by plating known numbers
of cells in a 12 well plate in culture medium containing mitomycin-C (Calbiochem).
Standard cell numbers were confirmed by a ViCell hemacytometer (Beckman-Coulter)
(data not shown).
3.2.5 Time Lapse VidoMicroscopy Assays
Surface Preparation
A solution of 3 ug/mL of human fibronectin (FN, Sigma) in PBS was used to coat
the bottom of a glass-bottom 24-well plate (MatTek) for 2 hours at room temperature,
followed by two PBS washes. A 1% (w/v) of BSA solution was then added to each well
to block any uncoated regions on the glass for 1 hr at room temperature. Each well was
then washed three times with PBS, and the plate was then UV-sterilized for 30 min.
CMFDA-Cell Tagging
A 1 tM solution of CellTracker Green (5-Chloromethylfluorescein diacetate)
from Molecular Probes (Invitrogen) was made by adding 10 uL of stock CMFDA (1 mM)
to 10 mL of a serum-free DMEM media containing: 1% L-glutamine, and 1%
penicillin/streptomycin. A 70-80% confluent htMSC petri dish washed with 10 mL of
sterile PBS followed by the addition of 10 mL of the CMFDA-containing serum-free
DMEM media. Cells were then incubated at 37'C, 95% humidity, and 5% C02 for 20
minutes. CMFDA-containing medium was then aspirated and replaced with 10 mL
serum-free DMEM media and incubated (37'C, 95% humidity, 5% C02) for 30 minutes.
Cells were then washed with sterile PBS followed by treatment with 5 mL of trypsin
(iX) solution. Upon cell detachment, adding 10 mL of growth medium blocked trypsin
action, and cell solution was spun down at 1000 rpm for 5 minutes. Growth media was
then aspirated and cell pellet was resuspended in 5 mL of quiescent media. Cell solution
was counted and diluted in quiescent media to give a concentration of 4000 cells per mL.
In a 24-well plate, 1.5 mL of cell solution was added per well to seed about 6000 cells per
well or about 5000 cells per cm 2. Cells were allowed to seed for 16-24 hours at 37'C,
95% humidity, 5% C02 conditions. After initial seeding time, medium was aspirated and
replaced with stimulation medium (quiescent medium containing ligand at known
concentration). The ligand solutions were prepared just before stimulation and
maintained at 37'C. Stimulation was carried out for 6 hours before beginning imaging.
Time-lapse Microscopy and Data Analysis
To generate time-lapse movies of cells migrating on the 2D FN coated surfaces,
GFP-widefield images were taken every 10 min for 12 h using a BD CARVII spinning
disk confocal with an Axio Observer Zeiss microscope equipped with environmental
control (37'C, 95% humidity, 5% C02). Cells were imaged using a field of view of 1306
x 13006 um with 2.551 x 2.551-um pixels. All movies with the slightest drifts in x or y-
direction were assessed and were not included for further analysis. Imaris (Bitplane,
Zurich, Switzerland) was used to visualize the 2D time-lapse images. The spots function
was used to calculate centroids of fluorescent CMFDA-htMSCs and migratory tracks of
individual cells were generated by using the Brownian motion tracking algorithm
previously described (H.-D. Kim et al, 2008). All generated tracks were then manually
verified for accuracy and modified when the automated logarithm presented errors. Cells
undergoing division, death as identified as the release of fluorescence, or blebbing were
not tracked. Additionally, cells were seeded on a surface at a low density to minimize any
cell-to-cell contact. Wind-Rose plots were generated from the tracks produced from
randomly choosing 50 tracks from the motile population and overlaying the starting
coordinates at the origin of the plots to graphically represent average cell dispersion
during migration. Only tracks longer than 2 hrs that had migrated independently without
physical contact with other cells were used for the calculation of directional persistence.
To calculate cell speed cell tracks were used as long as their migration was independent
of any physical contact with other cells and no cell death or division occurred during their
tracks. Average individual speeds (S) were calculated from individual cell tracks by
averaging the distances over the time interval. Mean squared displacements(MSD),
<d2>, at various time intervals (t) were calculated using the method of nonoverlapping
intervals (Dickinson and Tranquillo, 1993) and directional persistence time (P) was
obtained by fitting data to the persistent random walk model (PRW):
t
(d 2) 2S2P t- P(1- eP (3.1)
3.3 Results
3.3.1 Activation of EGFR and Erkl/2 Signaling by Bivalent EGF-containing
Ligands
We first examined the dose response for activation of EGFR in hT-MSC by the
bivalent ligands EE and EN, using a pan-phospho antibody. Stimulation by EGFR by
canonical ligands such as EGF typically leads to a dramatic increase in pEGFR within a
minute, peaking in the first few minutes, and a slow decay over 1-2 hr, as we have
previously illustrated for stimulation of hTMSC. Hence, to assess dose-response, we
measured pY-EGFR after 1 min and 15 min of stimulation by EE or EN (Fig 3.2). The
data are best fit with a two parameter model including a Hill coefficient as shown in
equation 3.2, where L is the ligand concentration and EC50 is a parameter representing
the dose of ligand which produces a half maximal response.
L2
= E (3.2)L2 + EC50
yielding an EC50 of 10 nM for stimulation by EE at both the 1 min and 15 min time
points (Fig 3.2). This value is slightly higher than the EC50 for wild type EGF. At
equimolar concentrations of bivalent ligand (which results in half the concentration of E
ligand for the case of EN compared to EE), EN stimulates only a fraction (at most, half)
of the signal of EE for pY-EGFR at both 1 min and 15 minutes post-stimulation, up to
ligand concentrations of 100 nM. To interpret these results, we consider the different
ways that EE and EN ligands can activate EGFR in the context of hTMSC, which are
known to express about 10,000 EGFR, 2,000 HER2, moderate levels of HER3 and no
HER4. Options for bivalent EE ligand include: (i) bivalent EE binds to individual EGFR
and acts essentially through only one EGF moiety, allowing both EGFR homodimers and
EGFR-HER2 heterodimers to form (ii) bivalent EE binds to EGFR and either stabilizes
pre-formed homodimers or drives homodimerization to the exclusion of
heterodimerization with HER2 (iii) bivalent EE ligand binds to individual EGFR through
a single EGF as described in (i), and two such individual, bivalent ligand-occupied
receptors homodimerize, allowing recruitment of additional free EGFR into oligomers
which may also include HER2.
In all of these scenarios, it is theoretically possible for essentially all cell surface
EGFR to bind ligand and become phosphorylated, through interactions with other ligand-
bound EGFR or with HER2. It is possible that dimer ligands may alter the kinetics of
phosphorylation/dephosphorylation compared to wtEGF, by imposing steric constraints
on the receptors, fostering different ratios of homo and heterodimers, or altering the
ability of the EGFR to interact with other cell surface receptors that are implicated in
transactivation. The theorectical limit of EGFR-HER2 heterodimers in these cells is
about one third of total possible EGFR in heterodimers when all EGFR are occupied and
dimerized (i.e., 2000 heterodimers and 4000 homodimers). Further, differences in the
relative phosphorylation of particular phosphosites may be affected by the receptor dimer
composition.
Using a similar analysis for the binding of bivalent EN, the possibilities are that
(i) bivalent EN binds to individual EGFR and acts essentially through only one EGF
moiety, allowing both EGFR homodimers and EGFR-HER2 heterodimers to form (ii)
bivalent EN binds to EGFR and drives heterodimerization with HER3 to the exclusion of
heterodimerization with HER2 (iii) bivalent EN ligand binds to individual EGFR through
a single EGF as described in (i), and two such individual, bivalent ligand-occupied
receptors homodimerize, allowing recruitment of HER3 into oligomers which may also
include HER2; (iv) bivalent EN binds to HER3 via a single NRG moiety, allowin HER2-
Her3 heterodimerization and possibly oligomerization, as well as HER3-Her3
homodimerization (v) bivalent EN binds to individual EGFR or HER3 but heterodimers
are sterically inhibited from forming.
If scenario (i) were predominant, we would expect similar responses from EE and
EN, presuming similar receptor-ligand affinities. The degree to which HER3 acts as a
"sink" as described in scenario EN (iv) or (v) is difficult to estimate precisely, because
the total number of HER3 relative to EGFR is unknown in these cells (presumed to be
<10,000), but is a plausible explanation for the effects observed. A more tenuous
explanation is that EGFR-HER3 heterodimers are relatively ineffective in these cells at
phosphorylating EGFR. Finally, we used a pan-pY antibody to assess phosphorylation. It
is also possible that the antibody reacts with different affinity to different pY sites on the
EGFR, or that more than one antibody can bind to a single pYEGFR if it is
phosphorylated on different sites, so that different patterns of pY on EGFR might result
in different signal strength even if the total number of pYEGFR is the same.
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Figure 3.2 - pTyrEGFR dose-response for EE and EN at 1 and 15 minutes
hTMSC were stimulated for 1 (A) or 15 minutes (B) with serial dilutions of EE (blue) or EN
(pink). Lysates were collected according to BioRad protocol and pTyrEGFR fluorescence
levels were measured by luminex technology as described in the materials and methods
section. Data were normalized by the average signal of the maximum BE concentration. The
experimental data were fitted to a Hill-function of first (solid line) and second-order (dashed
line). For EN, the model was weighted by the signal ratio at maximum concentration. At 15
minutes the models plotted here have an EC50 of 10 nM for EE and 50 nM for EN. Data are
shown from n=3 biological replicates. (figure courtesy of S. De Picciotto)
With the pY-EGFR dose-response in hand, we next examined the time course of EGFR
and HER2 activation using WT EGF and bivalent EE, under conditions of comparable
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EC5 0 and under conditions that should saturate the EGFR (i.e., concentrations 3-10 fold
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Figure 3.3 - Time course of EE and EGF stimulation
Data plotted in red are EGF-stimulated and in blue are EE-stimulated. A&B) Time course of
bivalent EGF ('EE') and wtEGF stimulation in hTMSC cells. Lysates were collected according to
Novagen protocol and pTyrEGFR (A) and pTyrHER2 (B) fluorescence levels were measured by
luminex technology as described in section 3.4. The figure represents normalized levels of
pTyrEGFR and pTyrHER2 with respect to an unstimulated control. Data are shown with n=3
biological replicates. C&D). Time course of bivalent EGF ('EE') and wtEGF stimulation in HeLa
cells at 100 nM. Errors are (+/-) standard error of the mean for n = 2 independent experimental
replicates. (figures A and B courtesy of S. De Picciotto)
For the EE saturating concentration we chose 100 nM because it is 3 times higher
than the EC5 0 of EE. For EGF we used 30 nM which is 30 times above its EC50 , therefore
signal maximum should be achieved, also this concentration is the same as the EC50 of
68
EE, thus we also have a means in each case of comparing EE and EGF at equimolar
concentrations. Finally, we stimulated the cells with 15 nM of EE because in this case the
number of EGF molecules (2 EGF molecules in EE) would be identical to 30 nM of EGF,
and with 1 nM EGF (EC50 of wtEGF).
From the data shown on figure 3.3 (A) and 3.3 (B), comparing each condition at
equimolar concentration, EGF-stimulated cells show both a stronger EGFR and HER2
phosphorylation than EE stimulated cells. However, for 100 nM EE stimulation (solid
blue curve), the phosphorylated EGFR levels are considerably higher over the whole
course of the experiment. Yet, this strong increase of phosphorylated EGFR for EE
compared to EGF is not correlated with an increase in pTyrHER2 signal. Indeed, even at
100 nM EE, the phosphorylated HER2 signal is lower than that of 1 nM EGF.
Weaker HER2 activation with bivalent EGF, EE, indicates that HER2 might be
prevented from dimerizing with EGFR by the bivalent EE ligand. At the saturating
concentrations (i.e., concentrations of ligand several-fold excess above EC5o) we would
expect all EGFR to be ligand-bound and phosphorylated, and thus expect comparable
levels of receptor activation for WT EGF and for the bivalent EE at saturating conditions.
The more robust phosphorylation signal for bivalent EE may indicate that EE alters
phosphorylation patterns and/or renders pY-EGFR less susceptible to phosphatase
activity.
It is notable that the pY-HER2 levels are significantly reduced for the bivalent
ligand EE case. Taken together, the results in Fig 3.3A and 3.3B suggest that EE is
capable of inhibiting EGFR-HER2 heterodimerzation, or at least, of allowing HER2 to
become activated if such dimers form.
We further explored the kinetics of EGFR activation and downstream signaling
using HeLa cells, as they express abundant EGFR and HER2. Using 100 nM EGF and
EE a marked increase (almost two-fold) of EGFR phosphorylation is observed in the EE-
stimulated case vs wtEGF over much of the early stimulation time course (<100
minutes). This observation suggests a differential effect exerted by EE vs wtEGF.
Further characterization of trafficking and dephosphorylation of the various Her-receptor
dimers would be required to definitively provide an explanation for these differences and.
Stimulation of EGFR prominently activates the downstream kinase pathway
leading to Erkl/2, a key signaling node integrating multiple signaling networks. 17, 25
Interestingly, despite the more robust EGFR signal elicited by EE bivalent ligands
compared to WT EGF (Fig 3.3C), activation of Erkl/2 is substantially lower for
stimulation by EE compared to WT EGF (Fig 3C). This observation is consistent with
previous findings by other groups which have shown reduced signaling potency of EGFR
homodimers compared to EGFR-Her2 heterodimers . Taken together these data suggest
that EE is able to bias EGFR dimerization toward homodimers compared to
heterodimers.
3.3.2 Manipulation of EFGR Family Signaling Pathways with Bivalent NRG-
Containing Ligands.
A major prediction of this work is that the bivalent neuregulin (NN) ligand should
shut off NRG-mediated signaling in cells where HER3 is expressed and where HER4 is
either not expressed or is able to be specifically excluded from binding NRG (e.g.,
through the use of blocking antibodies. Because HER3 is kinase-deficient, recruitment of
HER3 homodimers would produce a null signaling outcome. To assay this effect we
used two cell types that have known HER3 and HER4 expression profiles; MCF7s
known to express both HER3 and HER4; and htMSCs known to express only HER3.
Signaling mediated by wtNRG is typically robust and can be readily detected by
measuring pERK(1/2).
When hTMSC, which express HER3 but not HER4, are stimulated with
monovalent engineered NRG1, a robust dose-dependent pERK response is observed that
is similar for either configuration of the engineered ligand and similar to WT NRG1 (Fig
3.4). In stark contrast, stimulation with bivalent NN ligand appears to activate Erkl/2
modestly at low doses, but this mild effect is erased at higher ligand doses, suggesting
that the bivalent NN ligand captures HER3 in homodimers - which are inherently
incapable of downstream signal propagation.
Dose responses with bivalent EGF (EE) and mixed ligand EGF-NRG (EN) show
a rightward shifted EC50 (mid nM) and a steeper response region consistent with bivalent
avidity. A closer examination of the dose response curve and apparent avidity effects
produced with bivalent ligands which do signal is given in later sections. One possible
explanation for the rightward shifted EC50 is the exclusion of HER2 from receptor dimer
complexes. Jones demonstrated that HER2 plays a role in increasing ligand binding
affinity of both EGF to EGFR and NRG to HER3 (or HER4) and in the case of NRG
lowered the EC50 by one order of magnitude, thus suggesting a stabilizing role for
HER2, the exclusion of which could contribute to a reduction in apparent affinity as
evidence by the rightward shifted EC50.
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Figure - 3.4 Signal silencing in MSC cells with bivalent NRG (NN)
The effect of stimulating MSCs with a range of doses of various bivalent ligand combinations,
including comparisons of NN signaling. Signal is measured as pERK(1/2) levels relative to
unstimulated minima. Errors are (+/-) standard error of the mean for n = 3 independent
experimental replicates
The ability of the bivalent NN ligand to silence signaling through HER3
suggested a possible therapeutic use in cancer cell signaling. We therefore investigated
responses in a cancer cell line, MSCF, which expresses HER3 at a much more robust
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level than hTMSC. Because MCF7 also express HER4, which also binds NRG1, they are
a reasonable model for analyzing the effects of co-expression of Her 4. Figure 3.5 depicts
data from an inhibition experiment where bivalent neuregulin (NN) is used to inhibit
signaling in a dose dependent manner versus a 3 nM wtNRG challenge. Signal silencing
is mediated by the putative recruitment of HER3 homodimers to produce a silent
phenotype.
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Figure 3.5 - Signal silencing in MCF-7 cells with bivalent NRG (NN)
(A) The IC50 of N2 versus a 3 nM NRG challenge and effect of HER4 signaling are depicted.
Errors are (+/-) standard error of the mean for n = 3 independent experimental replicates. (B) a
representative immunoblot of an N2 IC50 experiment.
..........
Pretreatment of MCF7s with an anti-HER4(ECD) antibody specifically excludes
HER4 from ligand binding and thus excludes HER4 from participating in signaling
following wtNRG stimulation. Absence of anti-HER4 antibody pretreatment
reconstitutes wtNRG-stimulated signaling. The NN inhibition curve (circles) was fit with
a second order model to yield an IC50 of 12 nM and a Hill coefficient of n=2, which is
indicative of bivalent avidity.
Taken together, results from time course experiments in HeLas and inhibition in
MCF7s indicate that bivalent ligands may recruit respective HER receptors into dimeric
complexes of known composition and more importantly produce expected signaling
outcomes consistent with known mechanisms of ligand binding and receptor
dimerization.
3.3.2 Stimulation of MSC With Bivalent Ligands Influences Cell Migration
The effects of EGF family ligands on cell migration are well documented.26 The
stimulation of EGFR with EGF can give rise to increases in both speed and persistence.
To screen bivalent ligands for possible effects on cell migration phenotypes, we used
transwell migration assays. Transwell assays measure chemotactic migration and can
give a rapid readout of ligand effects that arise from modulated speed or persistence.
Although in a transwell experiment one cannot determine speed and persistence,
modulation of these parameters would manifest itself as a difference in transwell
migration. As seen in figure 3.6 monovalent ligands stimulate increased transwell
migration by approximately 40% and 25% for EGF and NRG, respectively. In contrast
all bivalent ligands produce reductions in transwell migration relative to an unstimulated
control. This is consistent with previous findings by Zhan et al. in which reduced
migration is observed for cells in which the predominant signaling mode is through
HERI homodimers.27 ,28
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Figure 3.6 - Inhibition of cell migration with bivalent ligands versus natural ligand
stimulation
Inhibition of cell migration with bivalent ligands forces HERl-1, HERl-3, and HER3-3
recpetor dimers versus natural ligand stimulation. Errors are (+/-) standard error of the mean
for n = 3 independent experimental replicates *p=0.01, **p=0.05 vs (-) control; n=3; Error
bars: 99% C.I. All ligands were dosed at 100 nM.
Although limited data are available on the effect of forced HERl-HER3 heterodimers on
migration it appears that exclusion of HER2 from signaling complexes may contribute to
this effect for all the bivalent ligand combinations studied here.
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Reduced transwell migration of cells stimulated with bivalent ligands may result
from the exclusion of HER2 from signaling complexes, as HER2 increases cell
29, 30persistence. If this is the case then the physical parameters which underlie cellular
motility should reflect this change. In the context of transwell migration the parameter of
directional persistence can be expected to play an important role in the fate of a cell. It is
reasonable to expect that a cell with reduced directional persistence would encounter a
transwell pore with a different frequency than a cell with high directional persistence. If
the frequency of encounters with a pore is reduced in cells with reduced directional
persistence then the number of opportunities to migrate through a pore would also be
reduced. In the case of a membrane with a sparse arrangement of pores relative to the
number of cells this is a reasonable assumption. Figure 3.7 illustrates the effect of
bivalent ligands on cellular persistence.
As expected, the bivalent ligands EN and NN appear to reduce the directional
persistence of cells. In particular this effect appears to be dose dependent in the case of
EN (figure 3.7, top), where the effect becomes statistically different than the control at
the EC50 of EN. In the case of EN and NN the effect is equivalent in magnitude and
appears to reflect the transwell migration results at the same dose (100 nM). The
reduction in directional persistence at this dose is approximately 55% versus the
unstimulated control. In terms of cell motility this means that a cell spends half as long
moving in one direction and will explore a smaller area over long times than cells with
higher persistence. By comparison the reduction in transwell migration was 50% for
bivalent ligand stimulation at this dose.
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Figure 3.7 - Persistence analysis: time-lapse micrcoscopy of 2D cell migration
Bivalent ligand stimulation with EN results in reduced directional persistence that is
dose dependent (top graph). Both EN and NN resulted in reduced directional
persistence of approximately 55% vs the EGF stimulated condition (bottom plot).
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3.3.2 Stimulation of Cells With Bivalent Ligands Influences Cell Survival and
Proliferation
The human telomerase reverse transcriptase immortalized human mesenchymal
stem cells used in the migration studies described above have been shown to survive
serum free conditions for several days if cultured at sufficiently high confluence (>50%).
While cell division is greatly reduced these cells can tolerate the absence of serum and
remain quiescent for a period of 3-7 days before undergoing programmed cell death.
This behavior presents a convenient breakpoint in cell fate that can be influenced by the
addition of survival stimuli such as EGF or NRG. Previous work has shown that MSCs
can be rescued from stressful or pro-death conditions by addition of EGF or NRG. The
ability of wild type ligands to rescue MSCs from apoptosis during stressful conditions is
mediated by signaling through the HER receptors which stimulates a number of pro-
survival down stream effectors. Variation in cell survival outcomes resulting from
stimulation with any of the bivalent ligands as compared to natural ligands would
indicate modulated signaling, perhaps related to biased receptor dimerization.
Figure 3.8 shows a set of photomicrographs of MSCs cultured for 30 days in
serum free medium containing the indicated conditions. Medium was changed every
three days during the 30 day period. After a period of 10 days the wells containing EGF
and EE showed early signs of apoptosis and reduced rates of medium acidification as
evidenced by phenol red indicator color.
After 14 days the wells containing NN and (-) showed similar characteristics. At
21 days the wells containing EGF, EE, NN, and (-) appeared to be completely dead and
no longer caused changes in phenol red indicator. Wells containing NRG and EN showed
a normal morphology and exhibited signs of metabolism by rapid acidification of
medium. The addition of NRG appears to confer a survival advantage under these
conditions which is consistent with previous findings. The addition of EN appears to
recapitulate this effect even though the presence of an EGF moiety in the bivalent
construct might be expected to counteract this effect based on the results from wild type
EGF stimulation. More strikingly, the NN condition did not perform better than the (-)
EGF EE
NRG EN NN
Figure 3.8 - Micrographs of cell cultures of htMSCs at 30 days
Stimulation with NRG and EN may promote viability in long term serum free
cultures. EGF, EE, and NN consistently result in reduced viability under these
conditions. The absence of viability in NN cultures corresponds with the expected
outcome given the silencing of signaling. Comparison of (-) with NN illustrates
the very similar outcomes. Scale bar is 100 am.
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control, a result which is entirely consistent with signaling the data showing no
stimulation of pERK in MSCs with NN.
The inhibition of signaling observed in MCF7 cells should also produce a
phenotypic survival differences under stressful conditions such as serum starvation. The
same conditions described in figure 3.4 were used to replicate the signaling effect but
were maintained for several days (48 to 96 hours, depending on the experiment).
Flow Cytometric Assay
96 hour serum starvation challenge
(100 nM NN)
(+) NRG-NRG (+) aHER4, NRG-NRG
acR4 Ab
TUNEL Assay
48 hour serum starvation challenge
(100 nM NN, 10 nM NRG)
(+)NRG (+)NRG.NRG
+ +
Figure 3.9 - Bivalent NRG effect on the survival of serum starved MCF7s
A significant increase in the %PI positive population of MCF7s results from treatment with
bivalent NRG under conditions which lead to signal attenuation through the HER3 and
HER4 mediated pathway. Likewise a significant increase in apoptotic (TUNEL positive)
cells is seen by 48 hours under the same conditions. These results are suggestive of the
proposed signaling attenuation mechanism. Left plot: *p=0.01 vs control (10 nM NRG),
**p=0.02 vs control (10 nM NRG), n=3, (+/-) SEM; Right plot *p=0.009 NN vs (-) control,
**p=0.001 NN vs 10 nM NRG; p=0.01 10 nM NRG vs (-), n=3, (+/-) s.d.
The extended time period under these conditions permits sufficient differences in survival
to be detected. Two types of assays were performed to study this effect in MCF7 cells: a
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cell permabilization assay which is a late marker of apoptosis and a terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay which measures
breaks in double stranded DNA, a mid to late maker of apoptosis. In the cell
permeabilization assay a total propidium iodide (PI) positive population is measured
using flow cytometry and gives a relative measure of cell death. TUNEL labeling is more
specific to apoptosis and gives a quantitative indication of cells undergoing programmed
cell death. Figure 3.9 shows the results of these two assays for MCF7 cells cultured
under the indicated conditions.
Imposing conditions which result in signal attenuation also result in increased cell
death under serum starvation. An increase of 35% in PI% cells is seen over the control
condition (figure 3.9, left). The exclusion of anti-HER4 antibody treatment allows NRG
to rescue cells from death (7% PI+) and reflects the signaling data shown earlier. The
TUNEL analysis shows the same effect. In this case the treatment that results in signal
attenuation produces 8% apoptotic cells vs <1% in the positive control. Phenotypic
results such as these agree well with the signaling data and support the proposed
mechanism of signal attenuation. These data are highly suggestive of the exclusion of
HER3 receptors from productive signaling complexes through the action of bivalent
NRG.
3.4 Conclusions
In this chapter it has been shown that bivalent HER ligands produce different
signaling patterns compared to their monovalent analogs. Current understanding of the
activation mechanism of HER receptors is still incomplete yet the system described here
may serve as a tool to elucidate some of these details. The results illustrated here
demonstrated that differential bivalent ligand signaling data are reflected in phenotypic
outcomes such as migration and survival. This could be of interest in applied contexts
such as tissue engineering or cancer. Further work in developing bivalent ligands for the
HER receptor system will likely yield valuable insights into this important regulator of
cell behavior.
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4 Discovery and application of BTCP binding peptides
4.1 Introduction
Beta-tricalcium phosphate (BTCP) is a clinically important material with broad
applications in bone repair. It is widely used in surgical procedures to fill bone voids and
serves as an important material in a variety of orthopedic compositions such as putties
and pastes that easily conform to wound geometries. Its continued evolution as a medical
product is limited by its material properties which do not permit direct chemical surface
modification and its physical properties which limit its handling. The ability to easily
modify the surface of BTCP would permit the design of molecular surface treatments
which would extend its bio-functionality and improve clinical performance. In this
chapter the discovery of a BTCP binding peptide and its subsequent engineering to
permit stable surface tethering of epidermal growth factor on BTCP is presented.
A key objective of this work is to demonstrate that tethered EGF results in
increased proliferation without compromising the early differentiation of primary human
MSCs cultured on 3D BTCP scaffolds. As important is the demonstration that tethered
EGF confers a strong survival advantage to MSCs cultured under serum starved
conditions for prolonged periods. This will serve to simulate the harsh conditions which
can exist in a wound following surgery. The approach described here can be adapted to
modify the surface of BTCP with a variety of proteins or peptides to achieve desired
phenotypes.
4.2 Proliferation versus multipotency: a regenerative medical challenge
The ability to expand a progenitor population without compromising
differentiation potential is one of the key objectives of regenerative medicine. Achieving
this effect would have significant clinical implications. Because many procedures rely on
autologous MSC transplantation, increasing patient native progenitor populations to
improve bone wound healing is an important objective.
Many studies have characterized the effects of EGF on tissues in vitro and in vivo.
EGF is the canonical ligand for the epidermal growth factor receptor (EGFR), and
induction of this pathway can produce proliferation,1-7 migration,8~11 homeostasis,3 and
synergistic effects leading to differentiation when dosed with other ligands.12-14 The
broad effects of this ligand result from the diversity of the downstream signaling network,
thus making EGF an important stimulus in wound healing contexts. In MSCs, EGF has
been shown to affect a number of cell behaviors in a context specific manner. EGF can
promote proliferation, 3 osteogenic differentiation,' 5 and survival.16 In a wound healing
context EGF can serve as an important cue leading to bone development and homeostasis
following surgery.17- 20 EGF has also been shown to play a role as a regulator of MSC
behavior'5'21-25 and can give rise to expansion of MSCs without inducing differentiation.3
The clinical utility of these effects cannot be fully exploited without a viable
method to deliver EGF to sites of injury in a spatially controlled manner; particularly on
clinically important substrates. One such clinically important substrate is BTCP which is
26
routinely used in orthopedic procedures. BTCP is an osteoconductive material that
supports bone mineralization by easily dissolving at low pH and serves as a rigid
5, 27substrate for cell attachment. 'Muschler and others have used this material in
conjunction with autologously harvested bone marrow to improve outcomes. In those
kinds of procedures the BTCP is flushed with bone marrow aspirate to seed MSCs and
27further promote bone formation.
Although the intrinsic properties of BTCP favor bone healing in many clinical
applications, addition of osteogenic growth factors BMP-2 and OP-1 to BTCP scaffolds
at the time of implant enhances healing in both experimental animal models and clinical
applications.28 It is reasonable to speculate that in large defects, where a source of stem
and/or progenitor cells (e.g. marrow aspirate) is added to overcome a local deficiency of
osteogenic cells, presentation of tethered EGF may enhance cell survival and stimulate
proliferation of early progenitors to populate the site, upstream of BMP activity.16, 29, 30
Although physisorption of PDGF to BTCP has been shown to enhance proliferation of
osteogenic cells on BTCP scaffolds in vitro, the in vivo loss of growth factor is much
faster than that observed in vitro.31 The utility of BTCP as an existing substrate for
orthopedic procedures would be enhanced if surface treatments were available to permit
stable attachment of bioactive components such as EGF.
4.3 Discovery of BTCP binding peptides using phage display
The approach taken to address this problem and which is described in detail in
this section is to discover novel peptide sequences that exhibit tight binding to BTCP by
using phage display. This approach has been used in other contexts to find peptide
sequences which bind inorganic substrates.3234 This section will describe the use of
sequences discovered through phage display as fusion partners to confer tight binding of
protein ligands to BTCP substrates. This concept is illustrated in figure 4.1 and includes
features from the bivalent ligand design to permit future work in bivalent ligand
presentation. This chapter will focus on monovalent ligand tethering studies.
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frTCP frTCP
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p-TCP p-TCP
Single Ligand Tethering Bivalent Ligand Tethering
Figure 4.1 - Ligand tethering concept using a BTXUI binding peptide (TCPBP)
Either single or bivalent ligand tethering is possible by retaining the coil region from
construct C1 (described in chapter 2).
4.4 Fabrication of BTCP and BTCP-polymer composite scaffolds
Scaffolds were fabricated at Therics (Akron, OH) from either BTCP or a
composite of BTCP and polylactide-co-glycolide (PLGA) using the TheriForm 3D rapid
prototyping platform.35 Briefly, to create BTCP scaffolds, granulated BTCP powder was
sintered and sieved. Scaffolds were fabricated in the shape of a cross by depositing binder
in a programmed sequence onto a BTCP powder bed and sucrose as a porogen. The
scaffolds were then sintered for 20 h, dried for 1 day, leached for 2 days to remove
porogen, and dried one day to yield crosses measuring 5 x 5 x 3mm (Figure 4.2). Each
implant is approximately 60% porous with a mean pore diameter of 60 microns and a
pore diameter range of 5-900 microns.
The internal structure shows an open spongy type structure (figure 4.x).
Chemically, the scaffolds are >95% BTCP with the remaining portion being other
resorbable forms of calcium phosphate. Composite BTPC-PLGA scaffolds were
.......... ........................
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fabricated in a similar fashion by mixing PLGA and BTCP powders with a porogen.
(more detailed manufacturing detail will be included in the manuscript).
Figure 4.2 - Photograph and scanning electron micrographs of a Therics Therilok
[-TCP scaffold; High magnification shows the detailed pore structure of these
scaffolds. (Scanning electron micrographs courtesy of L. Stockdale).
4.5 Phage display against BTCP scaffolds
BTCP scaffolds were crushed into powder, autoclaved for 35 minutes at 1214C
and stored under dry sterile conditions prior to all experiments. The resulting sterile
BTCP powder was blocked for 24 hours at 40C under moderate agitation with either
sterile filtered salmon protein buffer (Licor) or 5 % bovine serum albumin in phosphate
buffered saline (BSA, Sigma). Blocked BTCP powder was pelleted at 2000 RPM for 2
minutes, washed 3X with PBS then subjected to three rounds of phage display using the
New England Biolabs linear 12-mer Ph.D. kit (Andover, MA). Orthogonally blocked
BTCP (i.e. blocked with BSA vs salmon protein) provided a control against panning
against components of the blocking buffers. Additional controls included a -
BTCP/PLGA composite scaffold, crushed into powder, similarly blocked with BSA or
salmon protein buffer as well as a mock tube to control against panning against tube
components. After three rounds of panning, ten plaques from each condition were
picked, amplified, then sequenced (the mock condition and the BTCP/PLGA blocked
with BSA did not produce plaques after the second and third round, respectively).
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Sequences were analyzed for consensus using JalView Multiple Sequence Alignment
Editor.36 ,3 7 Figure 4.3 shows the aligned sequences.
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Figure 4.3- Multiple sequence alignment of phage clone sequences (left) and
concatenated peptide cloning concept (right)
A strong consensus sequence is immediately evident from the alignment. Eight of 29
sequences are identical (28%). Shading is based on the BLOSUM62 score. Concatenation
of multiple TCPBP regions results in increased affinity for bTCP. Generation of
concatenated multimers with a primer which contains the TCPBP coding region wholly
within the primer with no flanking sequences facilitates the creation of multiple insertion
clones per PCR reaction.
4.6 Mutagenesis
The highest ranked sequence from third round phage display panning.
(LLADTTHHRPWT) was serially cloned into a pMAL expression cassette using PCR
mutagenesis and a short primer to generate a library of multimer insertions fused to
epidermal growth factor (figure 4.3). PCR mutagenesis was performed with a
Quickchange Ligthtning II kit from Stratagene (Eugene, OR). Previous work in our lab
produced a pMAL-c2X vector (New England Biolabs) expressing human epidermal
............................. .
growth factor in fusion with various epitopes. PCR primers were designed to prime
wholly within the BTCP binding peptide coding region thus allowing multiple insertions
during a single PCR mutagenesis round. Multimer clones were sequenced to confirm
DNA identity with target sequence, transformed into BL21(DE3)pLysS E. coli and plated
on ampicillin LB agar. The library evaluated included (TCPBP)=1, 2, 3, 5, 8, andi1 clones.
4.7 Protein Expression
Clones of 1-, 2-, 3-, 5-, 8, and 10- mers of the TCPBP sequence
(LLADTTHHRPWT) were expressed in 1L LB cultures grown at 370C until OD 0.6,
then induced with IPTG and incubated at 220C for 4 hours. Proteins were harvested by
pelleting cultures at 3700 RPM on an Allegra G3.8 rotor at 4'C for 30 minutes then
freezing the pellet at -800C overnight followed by cell lysis using Bugbuster Reagent
(EMD Chemicals) supplemented with PMSF and protease inhibitor cocktail (Sigma).
Lysed cells were centrifuged at 3700 RPM on an Allegra G3.8 rotor at 40C for 1 hour.
The supernatant was then diluted 1:4 in tris buffered saline and subjected to maltose
binding protein affinity chromatography in accordance with the manufacturer's
instructions (New England Biolabs). Pooled fractions were subjected to ultrafiltration
through a 50,000 MWCO membrane U-tube concentrator (Novagen) and twice
exchanged into PBS. Concentrated protein was sterile filtered through a 0.2 micron filter.
Purity was confirmed by SDS-PAGE commassie staining. Protein quantification was
performed on a Nanodrop A280 spectrophotometer. Concentrated proteins were stored at
minus 800C until use. Based on preliminary results with 1- and 2-mers which showed
modest binding affinity, the 3-, 5-, and 10- mers were selected for further evaluation.
4.8 Tethering TCPBP-EGF on BTCP scaffolds and binding characterization
BTCP scaffolds or sieved pure BTCP powder was blocked for 1 hour with salmon
serum buffer then incubated at room temperature for two hours in purified TCPBP
protein diluted in salmon serum buffer. After incubation, scaffolds or powder were
washed three times in three volumes of 20 mM tris buffered saline at pH 7.4 followed by
a final wash and storage in PBS. Qualitative assessment of binding was performed by
fluorescence microscopy using a FITC-anti-HIS tag antibody and a goat-anti-hEGF
(R&D) primary and a TMR-anti-goat secondary as shown in figure 4.4. Control protein
incorporating all elements of the TCPBP sequence except the TCPBP region
(LLADTTHHRPWT)n was used as a negative control for non-specific binding in all
experiments (figure 4.4, bottom right). (For the manuscript time release studies will be
performed to determine the long term stability of tethered peptide.)
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Figure 4.4 - TCPBP binding characterization
(left) Immunofluorscence micrograph of TCPBP-EGF binding to sieved TCP powder
treated with (TCPBP)5-EGF or a control protein lacking the TCPBP region. All
images are 3 second exposures. Incubations performed at (i) 10 gM and (ii) 1 [M
(TCPBP)5-EGF, and (iii) 10 gM control EGF.
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Characterizing the binding of each of the concatenated multimers of TCPBP is
required in order to determine if increases in multimer insertion increase binding affinity
and to determine if the effect reaches a limiting value. Serial dilutions of TCPBP of 3-,
5-, and 10- multimers were incubated with BTCP as described above. Scaffolds were
then washed in PBS and bound protein was eluted by incubating the scaffolds in pH 2.2
glycine buffer for one hour and quantifying the amount of TCPBP in the eluate with IR-
dye immunofluorescence using a western blot format read with a Licor Odyssey IR
flatbed scanner. The results of this analysis are shown in figure 4.5.
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Figure 4.5 - Affinity of TCPBP for BTCP with increasing number of TCPBP repeats
(A) Clones incorporating 3, 5, and 10 repeats of the TCPCP sequence were assayed for
binding to TCP. (B) Bound protein was eluted from scaffolds and assayed by SDS-PAGE
& immunoblot. (C) Desitometry of bands from immunoblots reveals increasing amounts
of recovered protein for the same incubation concentration of TCPBP as the number of
TCPBP repeats is increased. (D) The slope of the fitted lines plotted versus number of
repeats reveals a strong dependence on TCPBP repeat number.
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TCPBP binding affinity exhibits a strong dependence on multimer number, as
expected. The relative change in affinity is illustrated in figure 4.5 (C) and (D). The
slope of the response signal as a function of (TCPBP)n incubation concentration gives a
relative indication of the retained protein which reflects the affinity at a given
concentration. Figure 4.5 (D) shows the strong dependence of repeat number on relative
affinity. Based on the multimer binding screen shown in figure 4.5 the 10-mer TCPBP
was selected for further experiments.
Quantitative analysis of binding was performed by incubating a serial dilution of
(TCPBP)IO with 35 mg intact TCP scaffolds treated as described above and analyzed
using a quantitative spot blot format read with a Licor Odyssey IR flatbed scanner. The
results of this analysis are shown in figures 4.6 and 4.7.
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Figure 4.6 - Quantification of (TCPBP)10-EGF affinity for BTCP
(A) Two microliters of standard curve dilutions of (TCPBP)10-EGF and control EGF
were spotted onto nitrocellulose membranes and probed with goat-a-EGF 1V and a-goat-
IRDye800 20 antibodies. (B) Spot intensity was correlated with the amount of protein
spotted to find (C) the linear range used for further quantification: 0 to 900 ng.
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Figure 4.7 - Quantification of (TCPBP)1o-EGF affinity for BTCP
(A) Two microliters of eluted (TCPBP)10-EGF or eluted control EGF were spotted onto
nitrocellulose membranes and probed with goat-a-EGF lo and a-goat-RDye800 2o
antibodies. No eluted control protein was detected. (B) Eluted protein fraction was
quantified and plotted as a function of incubation concentration. A two parameter
binding model was fit to the data: apparent Kd = 3.5 mM, Hill coeffcient = 2.3,
indicative of avidity. (C) Binding capacity of BTCP at various concentrations of
(TCPBP) -EGF. This curve can be used to tune the surface density of (TCPBP)10-
EGF on BTCP by selecting the appropriate incubation concentration.
Quantifying the amount of bound protein requires the creation of a standard curve
for both the sample and control protein. Figure 4.6 illustrates the results for the standard
curve. To make each curve a known amount of (TCPBP)lo or control (Cl protein as
shown in figure 4.4, bottom right) was blotted in quadruplicate onto a nitrocellulose
membrane and probed using the methods described above. The resulting signal produces
a monotonically increasing signal that begins to saturate at the higher end of the curve
(B). The first six points of this curve are in the linear range and are used to construct the
.. .................... . ............................... 
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standard curve. Because the epitope probed in both constructs is identical it is not
surprising that both the control and sample protein produced a standard curve with the
same slope. The range of protein that can be accurately quantified using this standard is 0
to 900 ng per 2 jiL spot.
The analysis of (TCPBP)10 binding to BTCP is shown in figure 4.7. The standard
curve permits direct quantification of bound protein and the construction of a binding
curve (B). This analysis produces an estimate for the binding constant kD of 2.3 uM. The
binding curve also exhibits avidity with a Hill coefficient of 2.3. This is consistent with
multimeric protein interactions. Brunauer, Emmet, Teller (BET) analysis of BTCP
scaffolds using a 5 point pressure analysis reveals an N2-accessible surface area of 0.8
m2/g. This permits the estimation of minimum surface number density as shown in (C).
The surface area accessible to EGF-(TCPB)10 may be less than the full N2 accessible
surface area if the pore size distribution occludes EGF-(TCPB)10 from accessing certain
regions of the scaffold. For the purposes of this analysis the discrepancy arising from this
effect is assumed to be negligible.
The data in figure 4.7, taken together with characteristic EGFR expression levels
indicate that the surface density of tethered EGF-(TCPB)10 is more than adequate to
stimulate MSCs at a maximal level. For example, at a tethering solution concentration of
1 [tM the tethered surface number density is 200 EGF(TCPBP)1o per jim 2. A spread cell
will have - 500 microns2 of surface area in contact with its substrate which would expose
it to -100,000 EGF molecules. By comparison, the typical MSC expresses 10,000
EGFRs. A significant fraction of these would encounter a tethered EGF over the course
of several minutes. In this system the EGFs are constrained at the substrate surface and
not as free to diffuse as with soluble EGF and so the kinetics of receptor ligand
interaction are not immediately analogous to the soluble case.
With a preliminary characterization of EGF(TCPBP)10 surface binding it is
possible to begin a preliminary analysis of cellular effects on a cell type that is clinically
relevant. The culture of a low passage (P3) primary human mesenchymal stem cells on
BTCP scaffolds treated with EGF(TCPBP)io is examined in the next section.
4.9 Cell Culture
Passage two primary human mesenchymal stem cells (from the Texas A&M
Health Science Center College of Medicine's Institute for Regenerative Medicine) were
culture expanded to provide sufficient numbers of passage three MSCs prior to all cell
culture experiments. Expansion medium consisted of aMEM with 2 mM L-glutamine,
16.5% fetal bovine serum, and penicillin/streptomycin (final concentration 100 units/ml
and 100 tg/ml streptomycin). Osteogenic medium consisted of 192 ml expansion
medium, 10 nM Dexamethasone (20 [d of a 1:10 dilution of a 1 mM stock in MQ water),
20 mM f-glycerolphosphate (8 ml of 0.5 M stock in expansion medium), and 50 pM L-
Ascorbic acid 2-phosphate (200 1d of 50 mM stock solution in MQ water
Sterile BTCP scaffolds were blocked with salmon serum buffer treated with
EGF(TCPBP)10 or left untreated and individually placed into the wells of a 96 well plate.
1,000 to 50,000 cells (as described) were seeded in 200 liL of serum-containing medium
(hTMSC) or expansion medium (primary MSC) per well directly onto the scaffolds.
Seeded cells were allowed to incubate for 24 hours then were moved into adjacent wells
with fresh medium to eliminate the effect of cells which did not seed onto the scaffolds.
Seeding effciciency with this method was consistently 40% as determined by counting
cells both on the scaffold and in the remnant well (described in the next section).
4.10 Proliferation Assays
Cellular proliferation was determined using the Alamar Blue assay (Biosource
Europe, Nivelle Belgium) at various time points post seeding. At each time point Alamar
Blue dye reagent was mixed with either osteogenic or expansion media according to the
manufacturer's instructions. Six biological replicates were seeded for each measurement.
The tethered BTCP scaffolds were then moved into a UV sterilized Falcon 96 well plate
(Becton Dickinson and Co., NJ USA) attached to a MDV series filter plate adapter
(Millipore, Bedford, MA). Alamar Blue dye reagent was then added to each well
containing a tethered BTCP scaffold and then incubated at 370C, 5% CO2 for four hours
with gentle mixing by hand every 20 minutes. The filter plate unit was then centrifuged at
1000 RPM for two minutes. This method allowed for complete recovery of dye-media
mixture. 100 uL of the resulting dye-media mixture was transferred from the collector
plate unit to a new flat-bottom 96-well plate to be read by a SpectraMax M2e multi-well
fluorescent plate reader (Molecular Devices Corp.CA, USA) at a 570 nm excitation
wavelength and 585 nm emission wavelength. A standard curve was obtained by
performing the same assay on known numbers of cells plated in a 12 well plate and
cultured for 1, 4, or 7 days to correspond to the respective time point. Because the
Alamar blue assay is non-destructive it was possible to directly count the cells with a
ViCell hemacytometer (Coulter) in order to calibrate the Alamar Blue signal response to
actual cell number.
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Hence, a standard curve for each culture condition (expansion medium 'EX' and
osteogenic medium 'OS') and each day time point up to 7 days was constructed to assess
the magnitude of variation. Metabolic rates under various conditions can vary. As
shown in figure 4.8 the slope of each standard curve is an indication of the metabolic
activity of the cells in that condition. Variations in the slope of the EX series at different
days indicates that cells undergo a shift in metabolism following seeding that can last
several days. Under OS medium the slope does not change significantly compared to the
day 1 EX (seeding condition). The respective slope for each culture condition and time
point was used to convert Alamar Blue data from the corresponding 3D scaffold
conditions into cell number. Day 14 and 21 cultures used the respective day 7 slopes.
Standard curves for days 14 and 21 were not reliable due to high confluence and cell
death at those time points.
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Figure 4.8 - Standard curves for the Alamar Blue based cell proliferation assay
Correlations between cell number and Alamar Blue fluorescence under each culture
condition were used to calibrate results for 3D cultures at each day time point up to 7
days. Cell cultured in osteogenic medium exhibited smaller changes in slope over time.
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4.11 Influence of cell seeding density and tEGF dose on MSC proliferation
The survival and proliferation of most mammalian cells exhibit a strong
dependence on local cell density. Cells secrete various autocrine factors that enhance
survival and proliferation at low cell densities and inhibit proliferation at high cell
densities. When the concentration of autocrine factors builds up at high cell densities we
expect that tEGF may enhance cell proliferation, but whether it can protect cells at very
low plating density, or overcome inhibition at high densities is unclear. We therefore
assess the proliferation response of MSCs to tEGF using a range of cell seeding densities
and surface tethering densities of tEGF.
By screening the effect of seeding density on proliferation profiles over a typical
time course it is possible to select a suitable density to use for future experiments. In
addition we expect that the surface density of EGF on BTCP can affect the proliferation
response of cells. EGF has been observed to exert a biphasic effect on cell proliferation
in 2D with concentrations near the EC50 (1 nM). In this system the EGF is tethered on
the surface and the equivalent EC50 can only be determined empirically. For the
purposes of this experiment cell proliferation is used as a proxy for dose response as
shown in figure 4.9.
Cell seeding densitities of 1,000; 25,000, and 50,000 cells per 200 ul (volume
used to seed each scaffold) were evaluated in expansion medium. The effect of seeding
density on proliferation is clearly evident at the 50,000 cell level in figure 4.9 (rightmost
plot). A significant drop in cell number is seen at day 4 with recovery by day 7. This
effect is much less pronounced at the 25,000 cell seeding level (center plot) and not
evident at the 1,000 cell seeding level. Based on these results a seeding density of 30,000
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cells per scaffold was selected. This level of seeding is a good compromise between
unwanted biphasic effects in proliferation and the amount of time required to obtain
sufficient cell material for other analyses (such as RNA for qRTPCR or protein for
alkaline phosphatase activity).
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Figure 4.9 - Proliferation of MSCs in expansion medium in 3D TCP scaffolds at
various cell seeding densities and EGF(TCPBP)10 tethering concentrations
All scaffolds incubated in EX medium and assayed at terminal endpoints using the Alamar
Blue based cell proliferation assay. Cell proliferation at high seeding densities (50K)
exhibited a sharp minimum at day 4. This effect is attenuated as seeding density is
reduced. Cell proliferation exhibited a biphasic relationship with respect to surface
EGF(TCPBP)10 tethering density at all seeding densities. The tethering concentrations
studied correspond to surface densities of 2,000; 400; and 60 EGF molecules / jim 2
* p=0.05 vs same day control, n=6, +/- s.d.
By day 7 cell proliferation exhibited a biphasic relationship with respect to
surface EGF(TCPBP)10 tethering density at all cell seeding densities, with an apparent
maximum at the 1.8 gM tethering concentration. This corresponds to 400 EGF
molecules / jim 2 . Based on these results a concentration of 1 jIM EGF(TCPBP)10 for
tethering was selected. A detailed examination of the effects of tethered EGF on
proliferation and osteogenic differentiation was carried out and is described in the
following section.
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4.12 Effect of tEGF on primary MSC proliferation in 3D BTCP scaffolds
The results of a detailed study of the effect of tEGF on MSC proliferation in both
EX and OS media are shown in figure 4.10. A cell seeding density of 30,000 per scaffold
and tethering concentration of 1 jM EGF(TCPBP)10 were used. In EX medium MSCs
exhibited approximately 50% increased proliferation vs the control at day 7. By day 14
this effect was no longer evident, with no significant difference between tEGF and
control. The parity at 14 days may be imposed by the carrying capacity of the scaffold at
high cell densities. With over 400,000 cells per scaffold there may be diffusive transport
limitations which impose constraints on EGF stiumulated proliferation. In OS medium
the effect of tEGF is more pronounced. At day 7 and 14 tEGF resulted in increases of
62% and 25% over controls, respectively. The increase in available MSCs in 3D
scaffolds is of particular interest in a clinical setting where scarcity of MSCs limits the
scope of procedures where autologous MSCs would be used.
An increase of 20-60% in the number MSCs at a wound site would significantly
improve outcomes and increase the size of defects which could be treated by taking
advantage of sparser seeding densities to achieve the same number as with current
methods. Whether these increases are significant from a clinical perspective requires
careful examination of the effects of tEGF on the early osteogenic differentiation of
MSCs in the same context. If the increase in proliferation is accompanied by a decrease
in osteogenic potential then the results will be less interesting. However, if early
differenation potential can be preserved or even improved then increases in proliferation
will have a meaningful effect on tissue formation at wound sites.
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Figure 4.10 - Proliferation of MSCs on 3D TCP scaffolds
tEGF promotes MSC proliferation in both EX and OS medium. Under OS conditions
increases of 62% and 25% at days 7 and 14, respectively, are observed for MSCs
cultured on scaffolds treated with tEGF. n=6, +/- s.d. *p=0.05 vs respective control.
105
4.13 Differentiation Assays
The ability of MSCs to underdo osteogenic differentiation is a useful metric to
assess the potency of these cells. Early osteogenic differentiation is typically measured
by comparing the alkaline phosphatase activity of induced cells with that of uninduced
cells. Later markers include panels of osteogenic transcripts as measured by qRTPCR
which give quantitative results. Even later (21 days) one can use mineralization assays
such as Alizarin red staining which stain deposited calcium. Given the limitation
imposed by 3D culture on calcium containing scaffolds this work will focus on alkaline
phosphatase assays and qRTPCR to assess osteogenic induction.
Alkaline phosphatase activity was measured using a p-nitrophenol colorimetric
assay. Scaffolds were rinsed with PBS twice followed by two freeze-thaw cycles (20 min
at -70"C followed by 10 min at 25'C). Two scaffolds from the same condition were added
to an epindorf tube, and then manually crushed with a pipet tip. Cells were lysed by
adding 200 pl of 0.2% NP-40 in 1 mmol/L MgCl 2 to each tube. The tubes were
incubated with medium shaking for 15 minutes at 4'C. After 5 min of sonication in a
water bath samples were centerfuged at 13,000 RPM for 5 minutes. The supernatant was
diluted 10-fold and 100-fold with lysis buffer. Diluted sample lysate and lysis buffer were
placed in 96-well plates with an all lysis buffer sample used as a background control. A
1:1 solution of 2-Amino-2-methyl-l-propanol, 1.5 mol/L, pH 10.3 at 258C (Sigma, Q17)
and stock substrate solution of p-nitrophenyl phosphate disodium (Sigma) was added to
the samples and incubated for 30 min at 37"C; sodium hydroxide was added to stop the
reaction. Absorbance at 405 nm was read using SpectraMax M2e multi-well fluorescent
plate reader (Molecular Devices Corp.CA, USA).
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Figure 4.11- Alkaline phosphatase activity assay (Day 7)
Alkaline phosphatase activity of primary human MSCs cultured on 3D TCP
scaffolds under the indicated conditions. Cells cultured in the tEGF OS
condition exhibit ALP activity that is comparable to that of OS alone.
Significantly, sEGF compromises this effect by lowering ALP activity. OS tEGF
is significantly different that EX control or OS+sEGF at p=0.05. n=3, +/- s.d.
(sEGF is soluble EGF at 1 ng/mL, tEGF is TCP treated with TCPBP as described
previously.)
Background signal from the blank control was subtracted from all readings. A serial
dilution of p-nitrophenol in sodium hydroxide was used to generate a standard curve in
U/mL: a unit is defined as the amount of enzyme which catalyses the liberation of 1
mmol p-nitrophenol per minute at 37'C. The results are normalized by total protein using
the BCA assay (Pierce).
The day 7 alkaline phosphatase activity (ALP) of MSCs grown in EX and OS
medium with and without soluble EGF and / or tethered EGF were compared as shown in
figure 4.11. OS (positive control) and OS+tEGF produced comparable levels as expected
which were the highest among the various conditions. Addition of soluble EGF at 1
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ng/mL abrogated the effect of osteogenic medium and resulted in activity which was
comparable to EX (negative control). Interestingly the addition of soluble EGF to the
Os+tEGF condition reduced overall ALP activity by almost 40%. This result appears to
confirm prior observations that surface tethered EGF may provide advantages over sEGF
by preserving osteogenic induction potential.
4.14 Qantitative real time polymerase chain reaction (q-RTPCR)
A set of osteogenic markers suitable for q-RTPCR was selected based on the
published literature in the field of osteogenesis and on previous work in this lab.
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Four markers of particular relevance in osteogenesis are discussed below.
RUNX2 is a transcription factor that is up-regulated in mechanically stressed pre-
osteoblasts and is a reliable indicator of bone forming activity. In osteoblasts there is
both a stretch dependent and stretch independent activation of RUNX2 which results in
activation of the mitogen activated protein kinase (MAPK) cascade. Interactions between
RUNX2 and pERK2 result in potentiation of RUNX2 activity. 38 The stimulation of
pERK1/2 via HERI by tEGF may result in amplification of RUNX2 activity through a
stretch-independent mechanism simply by virtue of pERK2 up-regulation. Thus
observation of up-regulation in RUNX2 activity in MSCs cultured on tEGF treated
scaffolds would have at least one mechanistic explanation given the common ERK
signaling node.
Osteocalcin (bone gamma-carboxyglutamic acid protein) is a small protein
associated with mineralized bone matrix. Hoang found that osteocalcin contains a
negatively charged surface that coordinates five calcium ions in an orientation that
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complements calcium ions in the hydroxyapatite crystal lattice of natural bone.
Osteocalcin is downstream of RUNX2 and has been shown to become up-regulated
following up-regulation of RUNX2.43
Osterix (SP7) is a zinc finger transcription factor and a regulator of bone cell
differentiation that is reported to operate downstream of RUNX2.40' Possible evidence
of this may be seen in figure 4.12 (bottom plots). Here the re-expression of osterix at day
14 following early RUNX2 upregulation under the tEGF condition at day 4 may be a
manifestation of this effect.
Osteonectin is a matrix protein that inhibits cell cycle progression and elicits
changes in cell morphology. It also exerts influence over the synthesis of extracellular
matrix in an osteogenic setting.4' It also binds to hydroxyapatite and collagen fibers at
distal sites accounting for the ability of bone collagen to undergo calcification. 39
3D BTCP scaffolds were treated with 1 gM EGF(TCPBP)io as described above
and seeded at 30,000 cells per scaffold. At the indicated time points RNA was harvested
from nine biological replicates per condition using a Qiagen RNEasy Plus II kit
(scaffolds were pooled into three biological replicates). The resulting RNA was
quantified, normalized to equal concentration then subjected to a two step q-RTPCR
reaction using a Qiagen Sybrgreen Quick kit and run on a Chromopho4 thermal cycler
with an optical sensor top. Each biological replicate was split into three technical
replicates. Melting curves were analyzed at the end of each run to confirm the absence of
contamination products. Primers for each gene were obtained from the Qiagen
Quantitect primer bank.
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Figure 4.12 - Timecourse of qRT-PCR of osteogenic markers
qRT-PCR data on a set of four osteogenic markers: osteonectin, osteocalcin, osterix, and
RUNX2 at days 4, 7, and 14 illustrates the effect of tethered EGF on expression levels of
early osteogenic differentiation markers. All four markers exhibit statistically significant
upregulation at day 14 (p<0.05) vs EX control. n=3 biological and m=3 technical
replicates, +/- s.d.
As shown in figure 4.12 all four gene products showed statistically significant up-
regulation at day 14 in the tEGF condition. Early up-regulation of RUNX2 of 5-fold may
have served as an early up-regulator of downstream factors such as osteocalcin and
osterix. A six-fold upregulation of osteonectin at day 14 is indicative of increased matrix
deposition as would be expected at later time points. The biphasic expression of
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osteocalcin, osterix, and RUNX2 with a minimum at day 7 may be indicative of changes
in cell cycle progression toward proliferation as seen in the proliferation data (figure
4.10). The effect of tEGF on the expression of key osteogenic factors during 3D cell
culture is a promising result, particularly when taking into consideration effects on
proliferation. Taken together these results give a strong indication that tEGF can
significantly increase proliferation of MSCs without compromising early osteogenic
differentitation. This finding is a positive result in meeting the important objective
outlined at the beginning of this chapter.
4.15 Long term survival assay using htMSCs
The impact of tEGF on the survival on MSCs has already been described here and
in the literature. Confirming these results in 3D tissue culture would permit extension of
these results into clinically relevant settings. The following section describes a long term
hTMSC survival assay designed to evaluate the effect of tEGF.
Human telomerase reverse transcriptase immortalized human mesenchymal stem
cells (htMSCs) were routinely cultured in Dulbecco's Modified Eagle Medium
supplemented with 10% fetal bovine serum for the htertMSCs and 16.5% for the primary
human MSCs, 2 mM L-glutamate, Na-pyruvate, non-essential amino acid supplement,
and penicillin/streptomycin (final concentration 100 units/ml and 100 ptg/ml
streptomycin). In certain experiments where indicated, serum was omitted from this
medium. Both nuclear staining and histological analysis of the tEGF treated scaffolds
shows marked differences in the amount of cellular invasion into the 3D BTCP scaffold
and of the relative survival effect at 23 days.
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The striking differences observed in figure 4.13 may have added relevance in surgical
settings where extensive wound sizes can present very harsh conditions for cell survival.
The rescue of already sparse MSCs in a harsh wound environment would be of great
clinical benefit.
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Figure 4.13 -Long term survival of htMSCs under serum starvation and
tEGF
(A) Surface treatment of BTCP with (TCPBP)5-EGF promotes the survival of
htMSC cells cultured in serum free medium for 23 days as seen with Cytox-16
nuclear DNA stain. Untreated scaffolds exhibit evidence of cell debris and do not
exhibit viable cell nuclei. (B) Hoechst and eosin stain of paraffin embedded
histology sections of scaffolds treated with (TCPBP)5-EGF show deep penetration
of cells into pore structure and morphology consistent with viable htMSCs.
Histological analysis of untreated scaffolds did not reveal any cell in-growth.
4.16 Conclusions
This work has demonstrated that MSCs cultured on BTCP scaffolds tethered with
EGF proliferate at a greater rate than those cultured on untreated scaffolds and that this
increase in proliferation does not compromise the early differentiation potential of MSCs.
Significantly, it has been shown that soluble EGF does not confer the same advantage
thus implicating a modulation of EGF bioactivity when presented as a matrix bound
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ligand. It is also clear that tethered EGF confers a strong survival advantage to htMSC
when cultured under extreme conditions such as serum starvation.
The ability to stably tether bioactive components to the surface of BTCP scaffolds
using the simple methods described in this study will permit a wide range of basic studies
in tissue regeneration and may lead to clinically useful approaches. One particularly
promising area is that of spatially guided tissue regeneration such as the vascularization
of regenerated bone and the regeneration of osteochondral interfaces.
4.17 References
1. Pinkas-Kramarski, R. et al. Diversification of Neu differentiation factor and
epidermal growth factor signaling by combinatorial receptor interactions. EMBO
J 15, 2452-2467 (1996).
2. Tzahar, E. et al. A hierarchical network of interreceptor interactions determines
signal transduction by Neu differentiation factor/neuregulin and epidermal growth
factor. Molecular and Cellular Biology 16, 5276-5287 (1996).
3. Tamama, K., Fan, V.H., Griffith, L.G., Blair, H.C. & Wells, A. Epidermal Growth
Factor as a Candidate for Ex Vivo Expansion of Bone Marrow-Derived
Mesenchymal Stem Cells. Stem Cells 24, 686 (2006).
4. Griffith, L.G. Emerging Design Principles in Biomaterials and Scaffolds for
Tissue Engineering. Annals of the New York Academy of Sciences 961, 83-95
(2002).
113
5. Muschler, G.F., Nakamoto, C. & Griffith, L.G. Engineering Principles of Clinical
Cell-Based Tissue Engineering. The Journal of Bone and Joint Surgery 86, 1541-
1558 (2004).
6. Bublil, E.M. & Yarden, Y. The EGF receptor family: spearheading a merger of
signaling and therapeutics. Current Opinion in Cell Biology 19, 124-134 (2007).
7. Citri, A. & Yarden, Y. EGF-ERBB signalling: towards the systems level. Nat Rev
Mol Cell Biol 7, 505-516 (2006).
8. Miettinen, P.J. et al. Epidermal growth factor receptor function is necessary for
normal craniofacial development and palate closure. Nature Genetics 22, 69-73
(1999).
9. Gibbs, S. et al. Epidermal growth factor and keratinocyte growth factor
differentially regulate epidermal migration, growth, and differentiation. Wound
Repair and Regeneration 8, 192-203 (2000).
10. Tokumaru, S. et al. Ectodomain Shedding of Epidermal Growth Factor Receptor
Ligands Is Required for Keratinocyte Migration in Cutaneous Wound Healing.
The Journal of Cell Biology 151, 209-220 (2000).
11. Maheshwari, G., Wells, A., Griffith, L.G. & Lauffenburger, D.A. Biophysical
Integration of Effects of Epidermal Growth Factor and Fibronectin on Fibroblast
Migration. Biophysical Journal 76, 2814-2823 (1999).
12. Traverse, S. et al. Research Paper EGF triggers neuronal differentiation of PC12
cells that overexpress the EGF receptor. Current Biology 4, 694-701 (1994).
13. Freeman, M. Reiterative use of the EGF receptor triggers differentiation of all cell
types in the Drosophila eye. Cell 87, 651-660 (1996).
114
14. Miettinen, P.J. Epidermal growth factor receptor function is necessary for normal
craniofacial development and palate closure, Nature Genetics, Vol. 127 (1999)
15. Kratchmarova, I., Blagoev, B., Haack-Sorensen, M., Kassem, M. & Mann, M.,
Vol. 308 1472-1477 (American Association for the Advancement of Science,
2005).
16. Fan, V.H. et al. Tethered Epidermal Growth Factor Provides a Survival
Advantage to Mesenchymal Stem Cells. Stem Cells 25, 1241 (2007).
17. Wang, K., Yamamoto, H., Chin, J.R., Werb, Z. & Vu, T.H. Epidermal Growth
Factor Receptor-deficient Mice Have Delayed Primary Endochondral Ossification
Because of Defective Osteoclast Recruitment. Journal of Biological Chemistry
279, 53848 (2004).
18. Sibilia, M. et al. Mice humanised for the EGF receptor display hypomorphic
phenotypes in skin, bone and heart. Development 130, 4515-4525 (2003).
19. Qin, L. et al. Amphiregulin Is a Novel Growth Factor Involved in Normal Bone
Development and in the Cellular Response to Parathyroid Hormone Stimulation.
Journal of Biological Chemistry 280, 3974 (2005).
20. Chan, S.Y. & Wong, R.W.C. Expression of Epidermal Growth Factor in
Transgenic Mice Causes Growth Retardation. Journal of Biological Chemistry
275, 38693-38698 (2000).
21. Kuznetsov, S.A., Friedenstein, A.J. & Gehron Robey, P. Factors required for bone
marrow stromal fibroblast colony formation in vitro. British Journal of
Haematology 97, 561-570 (1997).
115
22. Kimura, A., Katoh, 0. & Kuramoto, A. Effects of platelet derived growth factor,
epidermal growth factor and transforming growth factor-B on the growth of
human marrow fibroblasts. British Journal of Haematology 69, 9-12 (1988).
23. Gronthos, S. & Simmons, P.J. The growth factor requirements of STRO-1-
positive human bone marrow stromal precursors under serum-deprived conditions
in vitro. Blood 85, 929-940 (1995).
24. Owen, M.E., Clonal analysis in vitro of osteogenic differentiation of marrow
CFU-F, Vol. 87 731-738 (1987).
25. Satomura, K. et al. Receptor tyrosine kinase expression in human bone marrow
stromal cells. Journal of Cellular Physiology 177, 426-438 (1998).
26. Erbe, E.M., Marx, J.G., Clineff, T.D. & Bellincampi, L.D. Potential of an
ultraporous beta-tricalcium phosphate synthetic cancellous bone void filler and
bone marrow aspirate composite graft. Eur Spine J 10, S 141-146 (2001).
27. Fleming Jr, J.E., George, F., Muschler, C.B. & Isador, H. Intraoperative Harvest
and Concentration of Human Bone Marrow Osteoprogenitors for Enhancement of
Spinal Fusion. Orthopedic Tissue Engineering: Basic Science and Practice
(2004).
28. Friedlaender, G.E. et al., Vol. 83 151-158 (JBJS, 2001).
29. Marcantonio, N.A., Cynthia A. Boehm, Richard Rozic, Ada Au,a Alan Wells, &
George F. Muschler, L.G.G. Tethered epidermal growth factor increases
connective tissue progenitor colony formation. Stem Cells in press (2008).
116
30. Platt, M.O. et al. Sustained epidermal growth factor receptor levels and activation
by tethered ligand binding enhances osteogenic differentiation of multi-potent
marrow stromal cells. J Cell Physiol (2009).
31. Bateman, J. et al. Platelet-derived growth factor enhancement of two alloplastic
bone matrices. Journal ofperiodontology 76, 1833-1841 (2005).
32. Whaley, S.R., English, D.S., Hu, E.L., Barbara, P.F. & Belcher, A.M. Selection of
peptides with semiconductor binding specificity for directed nanocrystal
assembly. Nature 405, 665-668 (2000).
33. Sanghvi, A.B., Kiley, P., Miller, H., Belcher, A.M. & Schmidt, C.E. Biomaterials
functionalization using a novel peptide that selectively binds to a conducting
polymer. Nature Materials 4, 496-502 (2005).
34. Kenan, D.J. et al. Peptide-PEG amphiphiles as cytophobic coatings for
mammalian and bacterial cells. Chemistry & Biology 13, 695-700 (2006).
35. Zeltinger, J., Sherwood, J.K., Graham, D.A., Mueller, R. & Griffith, L.G. Effect
of pore size and void fraction on cellular adhesion, proliferation, and matrix
deposition. Tissue engineering 7, 557-572 (2001).
36. Schuler, G.D., Altschul, S.F. & Lipman, D.J. A workbench for multiple alignment
construction and analysis. Proteins: Structure, Function, and Genetics 9 (1991).
37. Clamp, M., Cuff, J., Searle, S.M. & Barton, G.J., Vol. 20 426-427 (Oxford Univ
Press, 2004).
38. Ziros, P.G. et al. The bone-specific transcriptional regulator Cbfal is a target of
mechanical signals in osteoblastic cells. Journal of Biological Chemistry 277,
23934-23941 (2002).
117
39. Termine, J.D. et al. Osteonectin, a bone-specific protein linking mineral to
collagen. Cell 26, 99-105 (1981).
40. Gao, Y., Jheon, A., Nourkeyhani, H., Kobayashi, H. & Ganss, B. Molecular
cloning, structure, expression, and chromosomal localization of the human
Osterix (SP7) gene. Gene 341, 101-110 (2004).
41. Bradshaw, A.D., Graves, D.C., Motamed, K. & Sage, E.H. SPARC-null mice
exhibit increased adiposity without significant differences in overall body weight.
Proceedings of the National Academy of Sciences 100, 6045-6050 (2003).
42. Hoang, Q.Q., Sicheri, F., Howard, A.J. & Yang, D.S.C. Bone recognition
mechanism of porcine osteocalcin from crystal structure. Nature 425, 977-980
(2003).
43. Mikami, Y., Omoteyama, K., Kato, S. & Takagi, M. Inductive effects of
dexamethasone on the mineralization and the osteoblastic gene expressions in
mature osteoblast-like ROS17/2.8 cells. Biochemical and Biophysical Research
Communications 362, 368-373 (2007).
44. Matsubara, T. et al. BMP2 regulates osterix through Msx2 and Runx2 during
osteoblast differentiation. Journal of Biological Chemistry 283, 29119 (2008).
118
5 Summary and Outlook
This thesis describes the foundational work carried out to make a system of
bivalent ligands targeting the HER family of receptors; a system which is capable of
profoundly altering cell phenotype. It also describes the discovery and application of an
engineered protein to functionalize an important clinical biomaterial in a way that
significantly increases the proliferation of low-passage primary human MSCs without
compromising osteogenic potential. Taken together these two efforts have established
the basic framework needed to apply the work to areas of clinical and biological
significance. It is hoped that future work in these areas can benefit from the ideas
presented in this thesis.
The bivalent ligand system described here offers a way to bias HER receptors
dimerization in a purely exogenous manner. This has immediate applications in the study
of the HER receptor system and potential applications in more applied areas such as
cancer research and tissue engineering. The nature of HER receptor dimerization and its
significance in a variety of biological contexts is currently the subject of intensive study.
Having an approach to directly control how HER receptors dimerize is valuable and the
system described here may serve as a tool to achieve these effects and answer important
questions in HER-related biology.
From the perspective of cancer biology it is well known that HER receptors play
an important role in defining many of the features of cancer cells.' The ability to control
even minor aspects of HER mediated signaling in cancer cells is of immediate interest.
The signal silencing effect exerted by bivalent NRG in hTMSCs and in MCF7s (breast
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cancer) is consistent with the proposed mechanism of action and is highly suggestive of
one approach to modulate signaling in cancer cells.
5.1 Future Work
5.1.1 Biophysical evidence of bivalent ligand effects
Future work with bivalent ligands may benefit from the collection of biophysical
evidence to validate the overall design. Several types of experiments could be performed
to determine if the bivalent ligand system controls dimerization as expected. These
include:
1. FRET measurements using HER 1 -CFP: HER3-YFP fusions
2. Receptor crosslinking and immunoblotting following ligand dosing
3. Immuno precipitation and immunoblotting following ligand dosing
4. Reporter complementation assay (luciferase or dihydrofolate reductase)
As an example, the development of a FRET sensor would permit direct
biophysical measurement of receptor association brought on by bivalent ligands. A
simple starting point to achieve this would be to carry out the subcloning CFY and YFP
as C-terminal fusions to HERI and HER-3, respectively. These two receptors are chosen
because the proposed ligand system can putatively stimulate HER1-3 heterodimers and
because detection of heterodimers is more straightforward than homodimers when using
a FRET system. The construction of the FRET reporter is accomplished through PCR
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mutagenesis of plasmids containing HERi and HER3 to introduce the C-terminal
fluorescent protein fusions CFP and YFP, respectively. The cloning will also introduce
flanking restriction sites to permit subcloning into an expression plasmid. The definitive
demonstration of bivalent ligand control over HER dimerization would come from a
statistically significant increase in YFP signal when dosing bivalent EGF-NRG ligand
(with appropriate controls). Other cell types which have low or null HERI (CHO cells),'
3 or HER3 backgrounds may be required to reduce the amount of endogenous untagged
receptor which could deplete signal generating receptor dimer pairs.
Biophysical evidence from radio-labeled binding experiments might also confirm
the observation of configurational avidity observed in signaling dose response
experiments.4 Figure 5.1 shows typical dose responses observed with monovalent and
bivalent ligands.
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Figure 5.1- Dose responses of htMSCs with monovalent (E) and bivalent ligand (EN)
Bivalent ligands consistently give dose responses which are steeper and exhibit Hill
coefficients -2 when fit with a two parameter model.
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The bivalent ligand dose response (EE or EN) consistently exhibits a steep
response region. A two parameter binding model fits the data well with a kd-30 nM and
a Hill coefficient of -2. A Hill coefficient > 1 is indicative of avidity and is supported by
the proposed binding of a bivalent ligand to a receptor dimer pair. Confirming this result
by measuring a direct binding isotherm with radiolabled bivalent ligand would be a
valuable finding suggestive of the proposed binding mechanism. Additional studies
along these lines are discussed in Appendix A.
5.1.2 Animal models of ectopic bone formation
A natural extension of the TCPBP work described in Chapter 4 is to examine the
effects of tEGF on ectopic bone formation in an animal model. Confirming the effects
observed thus far by using a simple but relevant animal model would support continued
work in this area and would justify studies of bone formation in larger animal models.
The ultimate goal of this work is to identify methods that can be used to treat large
segmental defects in humans, particularly where current methods fall short of
regenerating sufficient tissue to regain function. Although the regulatory hurdles
associated with implementing a TCPBP-EGF based approach are very high, the
demonstration of added benefit from spatially controlled delivery of biologically active
proteins to sites of injury would be immensely valuable and would prompt additional
efforts in this area.
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Appendix A - Stochastic 2D cell migration simulator
This appendix describes the details of a stochastic simulation of 2D cell migration
on a porous membrane. This simulation seeks to describe the impact of cell directional
persistence on transwell migration that may provide insights into the apparent correlation
between the transwell migration and reduced persistence in 2D cell migration described
in Chapter 3. The simulation is implemented in Matlab (Mathworks, Natick, MA). The
ability of the simulator to replicate real cell migration is illustrated in figure Al.
Parameters used to generate the ensemble of cell trajectories is shown under 'Inputs'.
Persistent Random Walk Simulation
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Figure Al - Evaluation of outputs from the simulation of 2D cell migration
The stochastic model of 2D cell migration should produce outputs which correlate well
with observed features of actual cell migration. Wind-rose plot, speed distribution for the
ensemble of cells, and mean square displacement as a function of time fitted with a
persistent random walk model (Dickinson and Tranquillo).
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A representative wind-rose plot for an ensemble of 200 cells is shown (top left). Each
cell is assigned a speed at each time step randomly selected from a normally distributed
cell speed distribution with a specified mean and standard deviation. An example of the
distribution of cell speeds resulting from a simulation is plotted in Figure Al (bottom
left), where a normal distribution is clearly evident. Fitting of the ensemble of MSDs
with a persistent random walk model is shown in figure Al ('Outputs' and bottom right).
Close agreement between the input parameters and the fitted outputs is a good indication
of the suitability of the stochastic simulator in capturing aspects of real cell migration
described by the PRWM. The persistence for each cell at each time step is randomly
sampled from a direction vector. In this case the direction vector is linearly arrayed with
no weighting distribution thus random re-sampling at each time step produces a Poisson
distributed set of persistences as shown in Figure A2 (rightmost histogram).
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Figure A2 - Evaluation of outputs from the simulation of 2D cell migration for a
single cell
Inputs: mean speed = 1 um/min, s.d. of speed = 0.1 um/min, persistence = 40 minutes
With the aid of this simulator it is possible to investigate simple questions about
cell migration. For example, for cells migrating on a 2D porous surface (such as a
transwell membrane) is the frequency of pore encounters correlated with directional
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persistence? This question may only likely be valid in conditions where cells are
sparsely seeded and migrating under conditions which probe chemokinesis as opposed to
chemotactic directional migration. In order to implement an instance of this question in
the simulator a few modifications are required. One is to introduce a pore field which is
representative of the distribution of pores in a transwell membrane and which have a
diameter characteristic of actual pores (8 um, in this case). Another is to randomize the
starting positions of cells on the 2D surface.
Figure A3 illustrates the results of three simulations of cell migration under
different persistence conditions. Qualitatively, one can observe that the frequency of pore
encounters is lower under conditions of low cell directional persistence by comparing the
number of pores (red dots) that do not meet a cell trajectory in the case of P=10 (leftmost)
with P=160 (rightmost).
4
P=10 min P=60 min P=160 min
Figure A3 -Simulation of 2D cell migration on a porous membrane at various levels of
directional persistence
Number of cells = 200, simulation time = 600 minutes, speed = 1 um/hr, persistence (as
indicated on each plot). Length is 2000 microns on a side. Red dots are 8 gm diameter pores.
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MATLAB Code Follows
%Persistent Random Walk Model Simulation of 2D Cell Migration on a Porous Membrane
%Luis Alvarez - April 2009
function migration
clear all
close all
n=600;
t=l;
timevector=linspace(0,n*t,n)';
T=t*n;
numcell=100;
%number of time steps to examine
%minutes per step
%total simulation time (minutes)
Inumber of cells
%% Generate a Gaussian speed distribution matrix
mean speed=l;
stdev speed=0.1;
s = (normrnd(mean speed,stdevspeed,10000,1));
s(find(s<0))=0;
in this %model
shist=0;
%microns/minute
% cells do not have %negative speed
%% Define persistence in terms of a unit directional vector
persistence=60;
number of directions=100;
p=2*numberofdirections*persistence;
dirvect=linspace(-1,1,p);
spread=2*p/persistence;
%% size of plot field
size=15*mean speed*n*t/sqrt(meanspeed*n*t);
based on how far cells move
% keeps plot window to %appropriate size
% Generate cell trajectories based on inputs
for j=l:numcell
aO=round(p*rand());
bO=round(p*rand());
x=zeros;
y=zeros;
%uncomment to give each cell a %random starting point
%x(l)=round(3*size*rand().*(-l)^round(3*rand());
%y(l)=round(3*size*rand() .*(-1)Around(3*rand());
speed=s(ceil(length(s)*rand());%use this line if you want to give
different but %constant speed throughout the simulation. To do
in the 'for loop' below to %'speed'. Assumes a different speed
from Gaussian speed distribution). %The %current default is to
the cell speed matrix at %each time step.
%each cell a
this change s(i)
(selected randomly
randomly resample
for i = 1:n-1
%aG=ceil(p*rand());
%b0=ceil(p*rand();
a0=(a0+spread*(-l)^ceil(rand(*2));
if aO>p aO=round(p*rand();%mod(aO,p);
end
if aO<1 a0=round(p*rand();%mod(absfaO),p);
end
if aO==0 aO=round(p*rand();
end
bO=(bO+spread*(-1)^ceil(rand()*2));
if bO>p bO=round(p*rand());%mod(bO,p);
end
if bO<l bO=round(p*rand();%mod(abs (bO,p);
end
if bO==0 bO=round(p*rand();
end
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dirx=dirvect(aO); %pick initial x direction index for dirvect
diry=dirvect(bO); %pick initial y direction index for dirvect
x(i+l)=x(i)+s(i)*(dirx)./sqrt((dirx).^2+(diry).^2); %sqrt corrects speed
%(pythagoras)
y(i+l)=y(i)+s(i)*(diry)./sqrt((dirx).^2+(diry).^2);
shist(i)=s(i)
end
%% cummulative (pathlength) and net (origin to end) distances
distancefromorigin=(x(end).^2+y(end).^2).^0.5;
cumdistance=(x.-2+y.^2).^0.5';
cumdistance=flipud(cumdistance);
%find the individual pathlenoths of each step by calculating the %difference between
%step n and n-1
for h=l:length(cum distance)-1;
suma(h)=cum distance(h)-cum distance(h+l)';
end
totaldistance=sum(abs(suma)'); %sum all the pathlengths to get the full %patlength
distancefromorigin/total distance*100;
std(abs(suma')); % a metric for persistence
persist=distance from origin/(speed*T);
%% Matrix of Cell Ensemble Data - this mod stores data from each cell
a=[x' y'];
EX(:,j)=a(:,1); i stores historical x positions for each cell
EY(:,j)=a(:,2); % stores historical y positions for each cell
EDAT(:,j)=[j; totaldistance; distancefromorigin;
distancefrom origin/totaldistance; persist];
end
%% Pore field
%find max min for X and Y to define extent of pore field (- [max min] %+/- 10 um)
maxX=max(max(EX));
minX=min(min(EX));
maxY=max (max (EY));
minY=min(min(EY));
npores=500/2;%nubmer of pores- will need 100 centers (a,b): (x-%a)^2+(y-b)^2=R^2:
R=4; % pore radius in microns
maxa=maxX; %keep pores inside cell field by subtracting R or adding R
mina=minX;
maxb=maxY;
minb=minY;
%Create pore field
porecentersapos=2*maxa*rand(npores,l);%generate 'npores' number of %centers
porecentersbpos=2*maxb*rand(npores,1);
porecentersaneg=2*mina*rand(npores,1);%generate 'npores' number of %centers
porecentersbneg=2*minb*rand(npores,1);
corl=ones(length(porecentersapos))*(-maxX);
corl=corl(:,1);
aa=[porecentersapos+corl; porecentersaneg];
bb=[porecentersbpos+corl; porecentersbneg];
XXX=0;
YYY=0;
botYYY=0;
for hh=l:npores
a=aa(hh);
b=bb(hh);
x=linspace(a-R, a+R);
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y=(R^2-(x-a).^2).^0.5+b;
ybot=-(R^2-(x-a).^2).^0.5+b;
XXX=[XXX x];
YYY=[YYY y];
botYYY= [botYYY,ybot];
end
%% PLOT results
figure(1)
%set(D, 'DefaultAxesColoriOrder', [1 0 0;0 1 0;0 0 1])
plot(EX,EY,'k-',XXX,YYY,'r.',XXX,botYYY,'r.') %,poresx,poresy, bo'
%plot(EX,EY, 'k-') %,poresx,poresy,'bo'
grid on
xlabel('x position (um)','fontsize',14,'fontweight','bold')
ylabel('y position (um)','fontsize',14,'fontweight','bold')
title('wind rose plot of cell tracks','fontsize',14,'fontweight','bold')
axis([-8*size 8*size -8*size 8*size])
set(gca,'fontsize',14,'fontweight','bold')
msd=mean(((EX.^2+EY.^2).^0.5).^2,2); % msd between steps: correct according to
Lauffenburger paper
beta=[meanspeed t]; %initial guess for <s^2> and P
beta = nlinfit(timevector,msd,@myrnodel,beta);
msd model=(2*beta(l)*beta(2).*timevector.*(l-beta(2)./timevector.*(l-exp(-
timevector./beta(2)))));
EDAT=EDAT';
sqdisp=EDAT(:,2).*EDAT(:,2);
'speed um/hr'
(beta(1).^0.5)*60
'persistence (min)'
round(beta(2))
msd-model(l)=0; %first value is NaN, need to set to zero.
RSQ=corrcoef(msd,msd model);
['R^2 = ', num2str(RSQ(2))]
'msd(end)^.5/(n*t) - um/hr'
(msd(end)).^0.5./(n*t)*60
%% this function is the persistent random walk model from Dickinson and Tranquillo:
% <d^2> = nd*Cs^2>*P*t* [l-P/t* (1-exp(-t/P))J
function yhat = mymodel(beta, timevector)
yhat = (2*beta(l).*beta(2).*timevector.*(l-beta(2)./timevector.*(l-exp(-
timevector./beta(2)))));
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